{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Abstract\n",
    "\n",
    "**Author:** [Charles Tapley Hoyt](https://github.com/cthoyt)\n",
    "\n",
    "**Estimated Run Time:** 1 minute\n",
    "\n",
    "This notebook demonstrates the utilities in [PyBEL Tools](http://pybel-tools.readthedocs.io) that facilitate the exploration and expansion of subgraphs to allow for easier interpretation and contextualization of their underlying mechanisms. The data used in this notebook comes from the [AETIONOMY](http://www.aetionomy.eu/) Alzheimer's Disease (AD) knowledge assembly that has been annotated with the [NeuromMMSig Database](http://neurommsig.scai.fraunhofer.de/pathways/introduction)."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Notebook Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "collapsed": false,
    "deletable": true,
    "editable": true
   },
   "outputs": [],
   "source": [
    "import logging\n",
    "import os\n",
    "import sys\n",
    "import time\n",
    "from collections import Counter, defaultdict\n",
    "from operator import itemgetter\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "import networkx as nx\n",
    "\n",
    "import pybel\n",
    "import pybel_tools as pbt\n",
    "from pybel.constants import *\n",
    "from pybel_tools.visualization import to_jupyter\n",
    "from pybel_tools.utils import barh, barv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": true,
    "deletable": true,
    "editable": true
   },
   "outputs": [],
   "source": [
    "%config InlineBackend.figure_format = 'svg'\n",
    "%matplotlib inline"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Notebook Provenance\n",
    "\n",
    "The time of execution and the versions of the software packegs used are displayed explicitly."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Tue Mar 21 18:27:04 2017'"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "time.asctime()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'0.4.3-dev'"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pybel.__version__"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'0.1.3-dev'"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pbt.__version__"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Local Path Definitions\n",
    "\n",
    "To make this notebook interoperable across many machines, locations to the repositories that contain the data used in this notebook are referenced from the environment, set in `~/.bashrc` to point to the place where the repositories have been cloned. Assuming the repositories have been `git clone`'d into the `~/dev` folder, the entries in `~/.bashrc` should look like:\n",
    "\n",
    "```bash\n",
    "...\n",
    "export BMS_BASE=~/dev/bms\n",
    "...\n",
    "```\n",
    "\n",
    "#### BMS \n",
    "\n",
    "The biological model store (BMS) is the internal Fraunhofer SCAI repository for keeping BEL models under version control. It can be downloaded from https://tor-2.scai.fraunhofer.de/gf/project/bms/"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "collapsed": true,
    "deletable": true,
    "editable": true
   },
   "outputs": [],
   "source": [
    "bms_base = os.environ['BMS_BASE']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Data\n",
    "\n",
    "The Alzheimer's Disease Knowledge Assembly has been precompiled with the following command line script, and will be loaded from this format for improved performance. In general, derived data, such as the gpickle representation of a BEL script, are not saved under version control to ensure that the most up-to-date data is always used.\n",
    "\n",
    "```sh\n",
    "pybel convert --path \"$BMS_BASE/aetionomy/alzheimers.bel\" --pickle \"$BMS_BASE/aetionomy/alzheimers.gpickle\"\n",
    "```\n",
    "\n",
    "The BEL script can also be compiled from inside this notebook with the following python code:\n",
    "\n",
    "```python\n",
    ">>> import os\n",
    ">>> import pybel\n",
    ">>> # Input from BEL script\n",
    ">>> bel_path = os.path.join(bms_base, 'aetionomy', 'alzheimers.bel')\n",
    ">>> graph = pybel.from_path(bel_path)\n",
    ">>> # Output to gpickle for fast loading later\n",
    ">>> pickle_path = os.path.join(bms_base, 'aetionomy', 'alzheimers.gpickle')\n",
    ">>> pybel.to_pickle(graph, pickle_path)\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "collapsed": true,
    "deletable": true,
    "editable": true
   },
   "outputs": [],
   "source": [
    "pickle_path = os.path.join(bms_base, 'aetionomy', 'alzheimers.gpickle')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "collapsed": true,
    "deletable": true,
    "editable": true
   },
   "outputs": [],
   "source": [
    "graph = pybel.from_pickle(pickle_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "collapsed": false,
    "deletable": true,
    "editable": true
   },
   "outputs": [],
   "source": [
    "# Add all canonical names for later\n",
    "pbt.mutation.add_canonical_names(graph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Connecting Components\n",
    "\n",
    "The GABA Subgraph is explored in this example. This subgraph contains a representative group of genes, RNAs, proteins, biological processes, and pathologies; and all of their relations. It is extracted with [pbt.selection.get_subgraph_by_annotation](http://pybel-tools.readthedocs.io/en/latest/selection.html#pybel_tools.selection.group_nodes_by_annotation_filtered)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "collapsed": true,
    "deletable": true,
    "editable": true
   },
   "outputs": [],
   "source": [
    "example_subgraph_name = 'GABA subgraph'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "subgraph = pbt.selection.get_subgraph_by_annotation(graph, annotation='Subgraph', value=example_subgraph_name)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "collapsed": false,
    "deletable": true,
    "editable": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: Alzheimer's Disease Model - (Subgraph: GABA subgraph)\n",
      "Number of nodes: 68\n",
      "Number of edges: 190\n",
      "Network density: 0.04170324846356453\n",
      "Number weakly connected components: 6\n",
      "Average in-degree: 2.7941176470588234\n",
      "Average out-degree: 2.7941176470588234\n"
     ]
    },
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height) {\n",
       "    const function_colors = {\n",
       "        \"Protein\": \"#1F77B4\",\n",
       "        \"Pathology\": \"#FF7F0E\",\n",
       "        \"BiologicalProcess\": \"#2CA02C\",\n",
       "        \"miRNA\": \"#D62728\",\n",
       "        \"Complex\": \"#9467bd\",\n",
       "        \"Composite\": \"#9467bd\",\n",
       "        \"Reaction\": \"#8c564b\",\n",
       "        \"Gene\": \"#e377c2\",\n",
       "        \"Abundance\": \"#bcbd22\",\n",
       "        \"RNA\": \"#17becf\"\n",
       "    };\n",
       "\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"ufkqahmxcrpvstzq\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {\"name\": \"Alzheimer's Disease Model - (Subgraph: GABA subgraph)\"}, \"pybel_version\": \"0.4.3.dev0\", \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}}], \"cname\": \"p(HGNC:GRIN2B, pmod(Ph))\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\", [\"pmod\", [\"bel\", \"Ph\"]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"cname\": \"EGR1\", \"id\": [\"Protein\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"synaptic transmission, cholinergic\", \"cname\": \"synaptic transmission, cholinergic\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"synaptic transmission, cholinergic\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"cname\": \"PSEN2\", \"id\": [\"Protein\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"cname\": \"TNF\", \"id\": [\"Protein\", \"HGNC\", \"TNF\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"cname\": \"GABRA1\", \"id\": [\"Protein\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"cname\": \"GABRA2\", \"id\": [\"Protein\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"Protein\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"Protein\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"Protein\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"cname\": \"GABRA6\", \"id\": [\"Protein\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"cname\": \"GABRB1\", \"id\": [\"Protein\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"cname\": \"GABRB2\", \"id\": [\"Protein\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"Protein\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"cname\": \"GABRG1\", \"id\": [\"Protein\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"cname\": \"GABRG2\", \"id\": [\"Protein\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"cname\": \"GABRG3\", \"id\": [\"Protein\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"cname\": \"GABRD\", \"id\": [\"Protein\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"cname\": \"GABRE\", \"id\": [\"Protein\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"cname\": \"GABRP\", \"id\": [\"Protein\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"cname\": \"GABRQ\", \"id\": [\"Protein\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"cname\": \"GABBR1\", \"id\": [\"Protein\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"cname\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of synaptic plasticity\", \"cname\": \"regulation of synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"cname\": \"GRIN2B\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cognition\", \"cname\": \"cognition\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cognition\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"learning\", \"cname\": \"learning\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"learning\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"memory\", \"cname\": \"memory\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"memory\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"cname\": \"CHRNA4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"gamma-aminobutyric acid\", \"cname\": \"gamma-aminobutyric acid\", \"id\": [\"Abundance\", \"CHEBI\", \"gamma-aminobutyric acid\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"glutamate(1-)\", \"cname\": \"glutamate(1-)\", \"id\": [\"Abundance\", \"CHEBI\", \"glutamate(1-)\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"cname\": \"CHRNB2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of neuronal synaptic plasticity\", \"cname\": \"regulation of neuronal synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of neuronal synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"cname\": \"CHRNA2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"cname\": \"CHRNA3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"cname\": \"CHRNA5\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"cname\": \"CHRNA6\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"cname\": \"CHRNA7\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"cname\": \"CHRNA9\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"cname\": \"CHRNA10\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"cname\": \"CHRNB3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"cname\": \"CHRNB4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"galanthamine\", \"cname\": \"galanthamine\", \"id\": [\"Abundance\", \"CHEBI\", \"galanthamine\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"1-(3-chlorophenyl)piperazine\", \"cname\": \"1-(3-chlorophenyl)piperazine\", \"id\": [\"Abundance\", \"CHEBI\", \"1-(3-chlorophenyl)piperazine\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"cname\": \"GABBR2\", \"id\": [\"Protein\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cAMP catabolic process\", \"cname\": \"cAMP catabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cAMP catabolic process\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEMBL\", \"name\": \"Nefiracetam\", \"cname\": \"Nefiracetam\", \"id\": [\"Abundance\", \"CHEMBL\", \"Nefiracetam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"cname\": \"PRKCA\", \"id\": [\"Protein\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"protein kinase A signaling\", \"cname\": \"protein kinase A signaling\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"protein kinase A signaling\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"cname\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"id\": [\"Abundance\", \"CHEBI\", \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"long-term synaptic potentiation\", \"cname\": \"long-term synaptic potentiation\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"long-term synaptic potentiation\"]}, {\"function\": \"Complex\", \"namespace\": \"SCOMP\", \"name\": \"CAMK2 Complex\", \"cname\": \"CAMK2 Complex\", \"id\": [\"Complex\", \"SCOMP\", \"CAMK2 Complex\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEMBL:Nefiracetam), p(HGNC:PRKCA))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEMBL\", \"Nefiracetam\"], [\"Protein\", \"HGNC\", \"PRKCA\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 831}], \"cname\": \"p(HGNC:GRIA1, pmod(Ph, Ser, 831))\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 831]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"cname\": \"GPHN\", \"id\": [\"Protein\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Glaucoma\", \"cname\": \"Glaucoma\", \"id\": [\"Pathology\", \"MESHD\", \"Glaucoma\"]}, {\"function\": \"Abundance\", \"namespace\": \"SCHEM\", \"name\": \"Glatiramer acetate\", \"cname\": \"Glatiramer acetate\", \"id\": [\"Abundance\", \"SCHEM\", \"Glatiramer acetate\"]}, {\"function\": \"Protein\", \"namespace\": \"MGI\", \"name\": \"Egr1\", \"cname\": \"Egr1\", \"id\": [\"Protein\", \"MGI\", \"Egr1\"]}, {\"function\": \"Complex\", \"cname\": \"complex(p(HGNC:EGR1), p(HGNC:PSEN2))\", \"id\": [\"Complex\", [\"Protein\", \"HGNC\", \"EGR1\"], [\"Protein\", \"HGNC\", \"PSEN2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"copper sulphate(5.H2O)\", \"cname\": \"copper sulphate(5.H2O)\", \"id\": [\"Abundance\", \"CHEBI\", \"copper sulphate(5.H2O)\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"RNA\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"RNA\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"RNA\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"RNA\", \"HGNC\", \"GABRA3\"]}], \"links\": [{\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 4, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 4, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 35, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 57, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 2, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 58, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Glaucoma\"}, \"source\": 3, \"target\": 59, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Alzheimer Disease\"}, \"source\": 3, \"target\": 59, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 6, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 5, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 3, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 3, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 6, \"target\": 4, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 13, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 14, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 15, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 17, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 19, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 21, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 22, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 23, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 30, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 35, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 36, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 37, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 31, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 38, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 39, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 40, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 41, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 42, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 34, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 43, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 44, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 18, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid β peptide (Aβ) and the Aβ x-42/Î‘β x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Dis. 2011 Feb;41(2):308-17. doi: 10.1016/j.nbd.2010.09.019. Epub 2010 Oct 1.\", \"reference\": \"20888417\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 47, \"target\": 48, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology (Berl). 1997 May;131(2):130-9\", \"reference\": \"9201800\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology (Berl). 1994 Mar;114(2):200-8\", \"reference\": \"7838908\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 50, \"key\": 0}, {\"relation\": \"causesNoChange\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 51, \"key\": 0}, {\"relation\": \"isA\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 52, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 53, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 55, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 54, \"target\": 56, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 44, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 57, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 58, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Glaucoma\"}, \"source\": 59, \"target\": 60, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Alzheimer Disease\"}, \"source\": 59, \"target\": 60, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 59, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 6, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Copper Sulfate results in increased expression of GABRA5 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549813\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 63, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Copper Sulfate results in decreased expression of GABRB3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549813\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 64, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 65, \"target\": 66, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of GABRA3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 65, \"target\": 67, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 66, \"target\": 65, \"key\": 0}]};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The subgraph also contains elements with important unqualified edges, like the relationships between complexes and their members. These relationships can be enriched from the original graph using the function [pbt.mutation.enrich_unqualified](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.enrich_unqualified). For example, the connection between `complex(p(HGNC:EGR1), p(HGNC:PSEN2))` and `p(HGNC:PSEN2)` is added during this process. The connection between the `p(HGNC:APP)` and `p(HGNC:APP, frag(672_713))` is also recovered."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "pbt.mutation.enrich_unqualified(graph, subgraph)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "collapsed": false,
    "deletable": true,
    "editable": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: Alzheimer's Disease Model - (Subgraph: GABA subgraph)\n",
      "Number of nodes: 69\n",
      "Number of edges: 197\n",
      "Network density: 0.041986359761295826\n",
      "Number weakly connected components: 4\n",
      "Average in-degree: 2.8550724637681157\n",
      "Average out-degree: 2.8550724637681157\n"
     ]
    },
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height) {\n",
       "    const function_colors = {\n",
       "        \"Protein\": \"#1F77B4\",\n",
       "        \"Pathology\": \"#FF7F0E\",\n",
       "        \"BiologicalProcess\": \"#2CA02C\",\n",
       "        \"miRNA\": \"#D62728\",\n",
       "        \"Complex\": \"#9467bd\",\n",
       "        \"Composite\": \"#9467bd\",\n",
       "        \"Reaction\": \"#8c564b\",\n",
       "        \"Gene\": \"#e377c2\",\n",
       "        \"Abundance\": \"#bcbd22\",\n",
       "        \"RNA\": \"#17becf\"\n",
       "    };\n",
       "\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"rkgqxjtbqpdusvco\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {\"name\": \"Alzheimer's Disease Model - (Subgraph: GABA subgraph)\"}, \"pybel_version\": \"0.4.3.dev0\", \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}}], \"cname\": \"p(HGNC:GRIN2B, pmod(Ph))\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\", [\"pmod\", [\"bel\", \"Ph\"]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"cname\": \"EGR1\", \"id\": [\"Protein\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"synaptic transmission, cholinergic\", \"cname\": \"synaptic transmission, cholinergic\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"synaptic transmission, cholinergic\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"cname\": \"PSEN2\", \"id\": [\"Protein\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"cname\": \"TNF\", \"id\": [\"Protein\", \"HGNC\", \"TNF\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"cname\": \"GABRA1\", \"id\": [\"Protein\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"cname\": \"GABRA2\", \"id\": [\"Protein\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"Protein\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"Protein\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"Protein\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"cname\": \"GABRA6\", \"id\": [\"Protein\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"cname\": \"GABRB1\", \"id\": [\"Protein\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"cname\": \"GABRB2\", \"id\": [\"Protein\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"Protein\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"cname\": \"GABRG1\", \"id\": [\"Protein\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"cname\": \"GABRG2\", \"id\": [\"Protein\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"cname\": \"GABRG3\", \"id\": [\"Protein\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"cname\": \"GABRD\", \"id\": [\"Protein\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"cname\": \"GABRE\", \"id\": [\"Protein\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"cname\": \"GABRP\", \"id\": [\"Protein\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"cname\": \"GABRQ\", \"id\": [\"Protein\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"cname\": \"GABBR1\", \"id\": [\"Protein\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"cname\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of synaptic plasticity\", \"cname\": \"regulation of synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"cname\": \"GRIN2B\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cognition\", \"cname\": \"cognition\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cognition\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"learning\", \"cname\": \"learning\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"learning\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"memory\", \"cname\": \"memory\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"memory\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"cname\": \"CHRNA4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"gamma-aminobutyric acid\", \"cname\": \"gamma-aminobutyric acid\", \"id\": [\"Abundance\", \"CHEBI\", \"gamma-aminobutyric acid\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"glutamate(1-)\", \"cname\": \"glutamate(1-)\", \"id\": [\"Abundance\", \"CHEBI\", \"glutamate(1-)\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"cname\": \"CHRNB2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of neuronal synaptic plasticity\", \"cname\": \"regulation of neuronal synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of neuronal synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"cname\": \"CHRNA2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"cname\": \"CHRNA3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"cname\": \"CHRNA5\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"cname\": \"CHRNA6\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"cname\": \"CHRNA7\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"cname\": \"CHRNA9\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"cname\": \"CHRNA10\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"cname\": \"CHRNB3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"cname\": \"CHRNB4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"galanthamine\", \"cname\": \"galanthamine\", \"id\": [\"Abundance\", \"CHEBI\", \"galanthamine\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"1-(3-chlorophenyl)piperazine\", \"cname\": \"1-(3-chlorophenyl)piperazine\", \"id\": [\"Abundance\", \"CHEBI\", \"1-(3-chlorophenyl)piperazine\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"cname\": \"GABBR2\", \"id\": [\"Protein\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cAMP catabolic process\", \"cname\": \"cAMP catabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cAMP catabolic process\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEMBL\", \"name\": \"Nefiracetam\", \"cname\": \"Nefiracetam\", \"id\": [\"Abundance\", \"CHEMBL\", \"Nefiracetam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"cname\": \"PRKCA\", \"id\": [\"Protein\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"protein kinase A signaling\", \"cname\": \"protein kinase A signaling\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"protein kinase A signaling\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"cname\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"id\": [\"Abundance\", \"CHEBI\", \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"long-term synaptic potentiation\", \"cname\": \"long-term synaptic potentiation\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"long-term synaptic potentiation\"]}, {\"function\": \"Complex\", \"namespace\": \"SCOMP\", \"name\": \"CAMK2 Complex\", \"cname\": \"CAMK2 Complex\", \"id\": [\"Complex\", \"SCOMP\", \"CAMK2 Complex\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEMBL:Nefiracetam), p(HGNC:PRKCA))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEMBL\", \"Nefiracetam\"], [\"Protein\", \"HGNC\", \"PRKCA\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 831}], \"cname\": \"p(HGNC:GRIA1, pmod(Ph, Ser, 831))\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 831]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"cname\": \"GPHN\", \"id\": [\"Protein\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Glaucoma\", \"cname\": \"Glaucoma\", \"id\": [\"Pathology\", \"MESHD\", \"Glaucoma\"]}, {\"function\": \"Abundance\", \"namespace\": \"SCHEM\", \"name\": \"Glatiramer acetate\", \"cname\": \"Glatiramer acetate\", \"id\": [\"Abundance\", \"SCHEM\", \"Glatiramer acetate\"]}, {\"function\": \"Protein\", \"namespace\": \"MGI\", \"name\": \"Egr1\", \"cname\": \"Egr1\", \"id\": [\"Protein\", \"MGI\", \"Egr1\"]}, {\"function\": \"Complex\", \"cname\": \"complex(p(HGNC:EGR1), p(HGNC:PSEN2))\", \"id\": [\"Complex\", [\"Protein\", \"HGNC\", \"EGR1\"], [\"Protein\", \"HGNC\", \"PSEN2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"copper sulphate(5.H2O)\", \"cname\": \"copper sulphate(5.H2O)\", \"id\": [\"Abundance\", \"CHEBI\", \"copper sulphate(5.H2O)\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"RNA\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"RNA\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"RNA\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"RNA\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"cname\": \"GRIA1\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\"]}], \"links\": [{\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 0, \"target\": 2, \"key\": -4}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 4, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 4, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 35, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 57, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 2, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 58, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Glaucoma\"}, \"source\": 3, \"target\": 59, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Alzheimer Disease\"}, \"source\": 3, \"target\": 59, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 6, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 5, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 3, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 3, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 6, \"target\": 4, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 13, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 14, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 15, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 17, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 19, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 21, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 22, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 23, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 30, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 27, \"target\": 1, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 35, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 36, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 37, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 31, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 38, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 39, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 40, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 41, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 42, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 34, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 43, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 44, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 18, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid β peptide (Aβ) and the Aβ x-42/Î‘β x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Dis. 2011 Feb;41(2):308-17. doi: 10.1016/j.nbd.2010.09.019. Epub 2010 Oct 1.\", \"reference\": \"20888417\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 47, \"target\": 48, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology (Berl). 1997 May;131(2):130-9\", \"reference\": \"9201800\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology (Berl). 1994 Mar;114(2):200-8\", \"reference\": \"7838908\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 50, \"key\": 0}, {\"relation\": \"causesNoChange\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 51, \"key\": 0}, {\"relation\": \"isA\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 52, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 53, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 55, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 54, \"target\": 56, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 44, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 49, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 50, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 57, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 58, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Glaucoma\"}, \"source\": 59, \"target\": 60, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Alzheimer Disease\"}, \"source\": 59, \"target\": 60, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 59, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 6, \"key\": 1}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 61, \"target\": 6, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 61, \"target\": 3, \"key\": -3}, {\"relation\": \"increases\", \"evidence\": \"Copper Sulfate results in increased expression of GABRA5 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549813\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 63, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Copper Sulfate results in decreased expression of GABRB3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549813\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 64, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 65, \"target\": 66, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of GABRA3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 65, \"target\": 67, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 66, \"target\": 65, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 68, \"target\": 56, \"key\": -4}]};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "deletable": true,
    "editable": true
   },
   "source": [
    "The graph also contains some related nodes, like `r(HGNC:GABRA5)` and `p(HGNC:GABRA5)` that are disconnected. Inferring the translation and transcriptional relationships between genes, RNAs, and proteins allows for connecting parts of the graph without much information. This can be accomplished with [pbt.mutation.infer_central_dogma](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.infer_central_dogma)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "pbt.mutation.infer_central_dogma(subgraph)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "collapsed": false,
    "deletable": true,
    "editable": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: Alzheimer's Disease Model - (Subgraph: GABA subgraph)\n",
      "Number of nodes: 141\n",
      "Number of edges: 273\n",
      "Network density: 0.013829787234042552\n",
      "Number weakly connected components: 2\n",
      "Average in-degree: 1.9361702127659575\n",
      "Average out-degree: 1.9361702127659575\n"
     ]
    },
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height) {\n",
       "    const function_colors = {\n",
       "        \"Protein\": \"#1F77B4\",\n",
       "        \"Pathology\": \"#FF7F0E\",\n",
       "        \"BiologicalProcess\": \"#2CA02C\",\n",
       "        \"miRNA\": \"#D62728\",\n",
       "        \"Complex\": \"#9467bd\",\n",
       "        \"Composite\": \"#9467bd\",\n",
       "        \"Reaction\": \"#8c564b\",\n",
       "        \"Gene\": \"#e377c2\",\n",
       "        \"Abundance\": \"#bcbd22\",\n",
       "        \"RNA\": \"#17becf\"\n",
       "    };\n",
       "\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"ejpgbqrvaqkosmhy\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {\"name\": \"Alzheimer's Disease Model - (Subgraph: GABA subgraph)\"}, \"pybel_version\": \"0.4.3.dev0\", \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}}], \"cname\": \"p(HGNC:GRIN2B, pmod(Ph))\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\", [\"pmod\", [\"bel\", \"Ph\"]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"cname\": \"EGR1\", \"id\": [\"Protein\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"synaptic transmission, cholinergic\", \"cname\": \"synaptic transmission, cholinergic\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"synaptic transmission, cholinergic\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"cname\": \"PSEN2\", \"id\": [\"Protein\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"cname\": \"TNF\", \"id\": [\"Protein\", \"HGNC\", \"TNF\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"cname\": \"GABRA1\", \"id\": [\"Protein\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"cname\": \"GABRA2\", \"id\": [\"Protein\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"Protein\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"Protein\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"Protein\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"cname\": \"GABRA6\", \"id\": [\"Protein\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"cname\": \"GABRB1\", \"id\": [\"Protein\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"cname\": \"GABRB2\", \"id\": [\"Protein\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"Protein\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"cname\": \"GABRG1\", \"id\": [\"Protein\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"cname\": \"GABRG2\", \"id\": [\"Protein\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"cname\": \"GABRG3\", \"id\": [\"Protein\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"cname\": \"GABRD\", \"id\": [\"Protein\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"cname\": \"GABRE\", \"id\": [\"Protein\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"cname\": \"GABRP\", \"id\": [\"Protein\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"cname\": \"GABRQ\", \"id\": [\"Protein\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"cname\": \"GABBR1\", \"id\": [\"Protein\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"cname\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of synaptic plasticity\", \"cname\": \"regulation of synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"cname\": \"GRIN2B\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cognition\", \"cname\": \"cognition\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cognition\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"learning\", \"cname\": \"learning\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"learning\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"memory\", \"cname\": \"memory\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"memory\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"cname\": \"CHRNA4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"gamma-aminobutyric acid\", \"cname\": \"gamma-aminobutyric acid\", \"id\": [\"Abundance\", \"CHEBI\", \"gamma-aminobutyric acid\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"glutamate(1-)\", \"cname\": \"glutamate(1-)\", \"id\": [\"Abundance\", \"CHEBI\", \"glutamate(1-)\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"cname\": \"CHRNB2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of neuronal synaptic plasticity\", \"cname\": \"regulation of neuronal synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of neuronal synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"cname\": \"CHRNA2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"cname\": \"CHRNA3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"cname\": \"CHRNA5\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"cname\": \"CHRNA6\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"cname\": \"CHRNA7\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"cname\": \"CHRNA9\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"cname\": \"CHRNA10\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"cname\": \"CHRNB3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"cname\": \"CHRNB4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"galanthamine\", \"cname\": \"galanthamine\", \"id\": [\"Abundance\", \"CHEBI\", \"galanthamine\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"1-(3-chlorophenyl)piperazine\", \"cname\": \"1-(3-chlorophenyl)piperazine\", \"id\": [\"Abundance\", \"CHEBI\", \"1-(3-chlorophenyl)piperazine\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"cname\": \"GABBR2\", \"id\": [\"Protein\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cAMP catabolic process\", \"cname\": \"cAMP catabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cAMP catabolic process\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEMBL\", \"name\": \"Nefiracetam\", \"cname\": \"Nefiracetam\", \"id\": [\"Abundance\", \"CHEMBL\", \"Nefiracetam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"cname\": \"PRKCA\", \"id\": [\"Protein\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"protein kinase A signaling\", \"cname\": \"protein kinase A signaling\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"protein kinase A signaling\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"cname\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"id\": [\"Abundance\", \"CHEBI\", \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"long-term synaptic potentiation\", \"cname\": \"long-term synaptic potentiation\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"long-term synaptic potentiation\"]}, {\"function\": \"Complex\", \"namespace\": \"SCOMP\", \"name\": \"CAMK2 Complex\", \"cname\": \"CAMK2 Complex\", \"id\": [\"Complex\", \"SCOMP\", \"CAMK2 Complex\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEMBL:Nefiracetam), p(HGNC:PRKCA))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEMBL\", \"Nefiracetam\"], [\"Protein\", \"HGNC\", \"PRKCA\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 831}], \"cname\": \"p(HGNC:GRIA1, pmod(Ph, Ser, 831))\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 831]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"cname\": \"GPHN\", \"id\": [\"Protein\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Glaucoma\", \"cname\": \"Glaucoma\", \"id\": [\"Pathology\", \"MESHD\", \"Glaucoma\"]}, {\"function\": \"Abundance\", \"namespace\": \"SCHEM\", \"name\": \"Glatiramer acetate\", \"cname\": \"Glatiramer acetate\", \"id\": [\"Abundance\", \"SCHEM\", \"Glatiramer acetate\"]}, {\"function\": \"Protein\", \"namespace\": \"MGI\", \"name\": \"Egr1\", \"cname\": \"Egr1\", \"id\": [\"Protein\", \"MGI\", \"Egr1\"]}, {\"function\": \"Complex\", \"cname\": \"complex(p(HGNC:EGR1), p(HGNC:PSEN2))\", \"id\": [\"Complex\", [\"Protein\", \"HGNC\", \"EGR1\"], [\"Protein\", \"HGNC\", \"PSEN2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"copper sulphate(5.H2O)\", \"cname\": \"copper sulphate(5.H2O)\", \"id\": [\"Abundance\", \"CHEBI\", \"copper sulphate(5.H2O)\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"RNA\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"RNA\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"RNA\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"RNA\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"cname\": \"GRIA1\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"cname\": \"APP\", \"id\": [\"RNA\", \"HGNC\", \"APP\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"cname\": \"EGR1\", \"id\": [\"RNA\", \"HGNC\", \"EGR1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"cname\": \"PSEN2\", \"id\": [\"RNA\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"cname\": \"TNF\", \"id\": [\"RNA\", \"HGNC\", \"TNF\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"cname\": \"GABRA1\", \"id\": [\"RNA\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"cname\": \"GABRA2\", \"id\": [\"RNA\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"cname\": \"GABRA6\", \"id\": [\"RNA\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"cname\": \"GABRB1\", \"id\": [\"RNA\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"cname\": \"GABRB2\", \"id\": [\"RNA\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"cname\": \"GABRG1\", \"id\": [\"RNA\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"cname\": \"GABRG2\", \"id\": [\"RNA\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"cname\": \"GABRG3\", \"id\": [\"RNA\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"cname\": \"GABRD\", \"id\": [\"RNA\", \"HGNC\", \"GABRD\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"cname\": \"GABRE\", \"id\": [\"RNA\", \"HGNC\", \"GABRE\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"cname\": \"GABRP\", \"id\": [\"RNA\", \"HGNC\", \"GABRP\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"cname\": \"GABRQ\", \"id\": [\"RNA\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"cname\": \"GABBR1\", \"id\": [\"RNA\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"cname\": \"GRIN2B\", \"id\": [\"RNA\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"cname\": \"CHRNA4\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"cname\": \"CHRNB2\", \"id\": [\"RNA\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"cname\": \"CHRNA2\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"cname\": \"CHRNA3\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"cname\": \"CHRNA5\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"cname\": \"CHRNA6\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"cname\": \"CHRNA7\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"cname\": \"CHRNA9\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"cname\": \"CHRNA10\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"cname\": \"CHRNB3\", \"id\": [\"RNA\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"cname\": \"CHRNB4\", \"id\": [\"RNA\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"cname\": \"GABBR2\", \"id\": [\"RNA\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"cname\": \"PRKCA\", \"id\": [\"RNA\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"cname\": \"GPHN\", \"id\": [\"RNA\", \"HGNC\", \"GPHN\"]}, {\"function\": \"RNA\", \"namespace\": \"MGI\", \"name\": \"Egr1\", \"cname\": \"Egr1\", \"id\": [\"RNA\", \"MGI\", \"Egr1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"cname\": \"GRIA1\", \"id\": [\"RNA\", \"HGNC\", \"GRIA1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"Gene\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"Gene\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"Gene\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"Gene\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"cname\": \"APP\", \"id\": [\"Gene\", \"HGNC\", \"APP\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"cname\": \"EGR1\", \"id\": [\"Gene\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"cname\": \"PSEN2\", \"id\": [\"Gene\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"cname\": \"TNF\", \"id\": [\"Gene\", \"HGNC\", \"TNF\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"cname\": \"GABRA1\", \"id\": [\"Gene\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"cname\": \"GABRA2\", \"id\": [\"Gene\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"cname\": \"GABRA6\", \"id\": [\"Gene\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"cname\": \"GABRB1\", \"id\": [\"Gene\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"cname\": \"GABRB2\", \"id\": [\"Gene\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"cname\": \"GABRG1\", \"id\": [\"Gene\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"cname\": \"GABRG2\", \"id\": [\"Gene\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"cname\": \"GABRG3\", \"id\": [\"Gene\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"cname\": \"GABRD\", \"id\": [\"Gene\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"cname\": \"GABRE\", \"id\": [\"Gene\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"cname\": \"GABRP\", \"id\": [\"Gene\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"cname\": \"GABRQ\", \"id\": [\"Gene\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"cname\": \"GABBR1\", \"id\": [\"Gene\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"cname\": \"GRIN2B\", \"id\": [\"Gene\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"cname\": \"CHRNA4\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"cname\": \"CHRNB2\", \"id\": [\"Gene\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"cname\": \"CHRNA2\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"cname\": \"CHRNA3\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"cname\": \"CHRNA5\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"cname\": \"CHRNA6\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"cname\": \"CHRNA7\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"cname\": \"CHRNA9\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"cname\": \"CHRNA10\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"cname\": \"CHRNB3\", \"id\": [\"Gene\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"cname\": \"CHRNB4\", \"id\": [\"Gene\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"cname\": \"GABBR2\", \"id\": [\"Gene\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"cname\": \"PRKCA\", \"id\": [\"Gene\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"cname\": \"GPHN\", \"id\": [\"Gene\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Gene\", \"namespace\": \"MGI\", \"name\": \"Egr1\", \"cname\": \"Egr1\", \"id\": [\"Gene\", \"MGI\", \"Egr1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"cname\": \"GRIA1\", \"id\": [\"Gene\", \"HGNC\", \"GRIA1\"]}], \"links\": [{\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 0, \"target\": 2, \"key\": -4}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 4, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 4, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 35, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 57, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 2, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 58, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Glaucoma\"}, \"source\": 3, \"target\": 59, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Alzheimer Disease\"}, \"source\": 3, \"target\": 59, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 6, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 5, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 3, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 3, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 6, \"target\": 4, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 13, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 14, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 15, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 17, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 19, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 21, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 22, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 23, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 30, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 27, \"target\": 1, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 35, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 36, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 37, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 31, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 38, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 39, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 40, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 41, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 42, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 34, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 43, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 44, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 18, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid β peptide (Aβ) and the Aβ x-42/Î‘β x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Dis. 2011 Feb;41(2):308-17. doi: 10.1016/j.nbd.2010.09.019. Epub 2010 Oct 1.\", \"reference\": \"20888417\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 47, \"target\": 48, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology (Berl). 1997 May;131(2):130-9\", \"reference\": \"9201800\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology (Berl). 1994 Mar;114(2):200-8\", \"reference\": \"7838908\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 50, \"key\": 0}, {\"relation\": \"causesNoChange\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 51, \"key\": 0}, {\"relation\": \"isA\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 52, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 53, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 55, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 54, \"target\": 56, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 44, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 49, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 50, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 57, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 58, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Glaucoma\"}, \"source\": 59, \"target\": 60, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Alzheimer Disease\"}, \"source\": 59, \"target\": 60, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 59, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 6, \"key\": 1}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 61, \"target\": 6, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 61, \"target\": 3, \"key\": -3}, {\"relation\": \"increases\", \"evidence\": \"Copper Sulfate results in increased expression of GABRA5 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549813\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 63, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Copper Sulfate results in decreased expression of GABRB3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549813\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 64, \"key\": 0}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 63, \"target\": 12, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 64, \"target\": 16, \"key\": -6}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 65, \"target\": 66, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of GABRA3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 65, \"target\": 67, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 66, \"target\": 65, \"key\": 0}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 66, \"target\": 11, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 67, \"target\": 10, \"key\": -6}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 68, \"target\": 56, \"key\": -4}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 69, \"target\": 0, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 70, \"target\": 3, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 71, \"target\": 6, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 72, \"target\": 7, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 73, \"target\": 8, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 74, \"target\": 9, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 75, \"target\": 13, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 76, \"target\": 14, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 77, \"target\": 15, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 78, \"target\": 17, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 79, \"target\": 18, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 80, \"target\": 19, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 81, \"target\": 20, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 82, \"target\": 21, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 83, \"target\": 22, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 84, \"target\": 23, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 85, \"target\": 24, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 86, \"target\": 27, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 87, \"target\": 31, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 88, \"target\": 34, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 89, \"target\": 36, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 90, \"target\": 37, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 91, \"target\": 38, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 92, \"target\": 39, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 93, \"target\": 40, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 94, \"target\": 41, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 95, \"target\": 42, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 96, \"target\": 43, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 97, \"target\": 44, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 98, \"target\": 47, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 99, \"target\": 50, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 100, \"target\": 57, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 101, \"target\": 60, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 102, \"target\": 68, \"key\": -6}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 103, \"target\": 63, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 104, \"target\": 64, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 105, \"target\": 66, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 106, \"target\": 67, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 107, \"target\": 69, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 108, \"target\": 70, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 109, \"target\": 71, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 110, \"target\": 72, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 111, \"target\": 73, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 112, \"target\": 74, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 113, \"target\": 75, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 114, \"target\": 76, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 115, \"target\": 77, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 116, \"target\": 78, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 117, \"target\": 79, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 118, \"target\": 80, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 119, \"target\": 81, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 120, \"target\": 82, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 121, \"target\": 83, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 122, \"target\": 84, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 123, \"target\": 85, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 124, \"target\": 86, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 125, \"target\": 87, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 126, \"target\": 88, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 127, \"target\": 89, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 128, \"target\": 90, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 129, \"target\": 91, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 130, \"target\": 92, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 131, \"target\": 93, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 132, \"target\": 94, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 133, \"target\": 95, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 134, \"target\": 96, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 135, \"target\": 97, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 136, \"target\": 98, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 137, \"target\": 99, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 138, \"target\": 100, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 139, \"target\": 101, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 140, \"target\": 102, \"key\": -5}]};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Finally, some of the genes and RNAs that have been added have no connections, and can be removed with [pbt.mutation.prune_central_dogma](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.prune_central_dogma)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "pbt.mutation.prune_central_dogma(subgraph)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "collapsed": false,
    "deletable": true,
    "editable": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: Alzheimer's Disease Model - (Subgraph: GABA subgraph)\n",
      "Number of nodes: 69\n",
      "Number of edges: 201\n",
      "Network density: 0.04283887468030691\n",
      "Number weakly connected components: 2\n",
      "Average in-degree: 2.9130434782608696\n",
      "Average out-degree: 2.9130434782608696\n"
     ]
    },
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height) {\n",
       "    const function_colors = {\n",
       "        \"Protein\": \"#1F77B4\",\n",
       "        \"Pathology\": \"#FF7F0E\",\n",
       "        \"BiologicalProcess\": \"#2CA02C\",\n",
       "        \"miRNA\": \"#D62728\",\n",
       "        \"Complex\": \"#9467bd\",\n",
       "        \"Composite\": \"#9467bd\",\n",
       "        \"Reaction\": \"#8c564b\",\n",
       "        \"Gene\": \"#e377c2\",\n",
       "        \"Abundance\": \"#bcbd22\",\n",
       "        \"RNA\": \"#17becf\"\n",
       "    };\n",
       "\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"crzdhtjuqgpmeoka\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {\"name\": \"Alzheimer's Disease Model - (Subgraph: GABA subgraph)\"}, \"pybel_version\": \"0.4.3.dev0\", \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}}], \"cname\": \"p(HGNC:GRIN2B, pmod(Ph))\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\", [\"pmod\", [\"bel\", \"Ph\"]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"cname\": \"EGR1\", \"id\": [\"Protein\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"synaptic transmission, cholinergic\", \"cname\": \"synaptic transmission, cholinergic\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"synaptic transmission, cholinergic\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"cname\": \"PSEN2\", \"id\": [\"Protein\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"cname\": \"TNF\", \"id\": [\"Protein\", \"HGNC\", \"TNF\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"cname\": \"GABRA1\", \"id\": [\"Protein\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"cname\": \"GABRA2\", \"id\": [\"Protein\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"Protein\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"Protein\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"Protein\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"cname\": \"GABRA6\", \"id\": [\"Protein\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"cname\": \"GABRB1\", \"id\": [\"Protein\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"cname\": \"GABRB2\", \"id\": [\"Protein\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"Protein\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"cname\": \"GABRG1\", \"id\": [\"Protein\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"cname\": \"GABRG2\", \"id\": [\"Protein\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"cname\": \"GABRG3\", \"id\": [\"Protein\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"cname\": \"GABRD\", \"id\": [\"Protein\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"cname\": \"GABRE\", \"id\": [\"Protein\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"cname\": \"GABRP\", \"id\": [\"Protein\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"cname\": \"GABRQ\", \"id\": [\"Protein\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"cname\": \"GABBR1\", \"id\": [\"Protein\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"cname\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of synaptic plasticity\", \"cname\": \"regulation of synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"cname\": \"GRIN2B\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cognition\", \"cname\": \"cognition\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cognition\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"learning\", \"cname\": \"learning\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"learning\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"memory\", \"cname\": \"memory\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"memory\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"cname\": \"CHRNA4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"gamma-aminobutyric acid\", \"cname\": \"gamma-aminobutyric acid\", \"id\": [\"Abundance\", \"CHEBI\", \"gamma-aminobutyric acid\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"glutamate(1-)\", \"cname\": \"glutamate(1-)\", \"id\": [\"Abundance\", \"CHEBI\", \"glutamate(1-)\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"cname\": \"CHRNB2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of neuronal synaptic plasticity\", \"cname\": \"regulation of neuronal synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of neuronal synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"cname\": \"CHRNA2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"cname\": \"CHRNA3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"cname\": \"CHRNA5\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"cname\": \"CHRNA6\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"cname\": \"CHRNA7\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"cname\": \"CHRNA9\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"cname\": \"CHRNA10\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"cname\": \"CHRNB3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"cname\": \"CHRNB4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"galanthamine\", \"cname\": \"galanthamine\", \"id\": [\"Abundance\", \"CHEBI\", \"galanthamine\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"1-(3-chlorophenyl)piperazine\", \"cname\": \"1-(3-chlorophenyl)piperazine\", \"id\": [\"Abundance\", \"CHEBI\", \"1-(3-chlorophenyl)piperazine\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"cname\": \"GABBR2\", \"id\": [\"Protein\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cAMP catabolic process\", \"cname\": \"cAMP catabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cAMP catabolic process\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEMBL\", \"name\": \"Nefiracetam\", \"cname\": \"Nefiracetam\", \"id\": [\"Abundance\", \"CHEMBL\", \"Nefiracetam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"cname\": \"PRKCA\", \"id\": [\"Protein\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"protein kinase A signaling\", \"cname\": \"protein kinase A signaling\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"protein kinase A signaling\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"cname\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"id\": [\"Abundance\", \"CHEBI\", \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"long-term synaptic potentiation\", \"cname\": \"long-term synaptic potentiation\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"long-term synaptic potentiation\"]}, {\"function\": \"Complex\", \"namespace\": \"SCOMP\", \"name\": \"CAMK2 Complex\", \"cname\": \"CAMK2 Complex\", \"id\": [\"Complex\", \"SCOMP\", \"CAMK2 Complex\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEMBL:Nefiracetam), p(HGNC:PRKCA))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEMBL\", \"Nefiracetam\"], [\"Protein\", \"HGNC\", \"PRKCA\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 831}], \"cname\": \"p(HGNC:GRIA1, pmod(Ph, Ser, 831))\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 831]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"cname\": \"GPHN\", \"id\": [\"Protein\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Glaucoma\", \"cname\": \"Glaucoma\", \"id\": [\"Pathology\", \"MESHD\", \"Glaucoma\"]}, {\"function\": \"Abundance\", \"namespace\": \"SCHEM\", \"name\": \"Glatiramer acetate\", \"cname\": \"Glatiramer acetate\", \"id\": [\"Abundance\", \"SCHEM\", \"Glatiramer acetate\"]}, {\"function\": \"Protein\", \"namespace\": \"MGI\", \"name\": \"Egr1\", \"cname\": \"Egr1\", \"id\": [\"Protein\", \"MGI\", \"Egr1\"]}, {\"function\": \"Complex\", \"cname\": \"complex(p(HGNC:EGR1), p(HGNC:PSEN2))\", \"id\": [\"Complex\", [\"Protein\", \"HGNC\", \"EGR1\"], [\"Protein\", \"HGNC\", \"PSEN2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"copper sulphate(5.H2O)\", \"cname\": \"copper sulphate(5.H2O)\", \"id\": [\"Abundance\", \"CHEBI\", \"copper sulphate(5.H2O)\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"cname\": \"GABRA5\", \"id\": [\"RNA\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"cname\": \"GABRB3\", \"id\": [\"RNA\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"cname\": \"GABRA4\", \"id\": [\"RNA\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"cname\": \"GABRA3\", \"id\": [\"RNA\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"cname\": \"GRIA1\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\"]}], \"links\": [{\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 0, \"target\": 2, \"key\": -4}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 4, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 4, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 35, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 57, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 2, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 58, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Glaucoma\"}, \"source\": 3, \"target\": 59, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Alzheimer Disease\"}, \"source\": 3, \"target\": 59, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 3, \"target\": 6, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 5, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 3, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 3, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 6, \"target\": 4, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 13, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 14, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 15, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 17, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 19, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 21, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 22, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 23, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF- Î± can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators Inflamm. 2014;2014:861231\", \"reference\": \"24966471\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 30, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 27, \"target\": 1, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 35, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 36, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 37, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 31, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 38, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 39, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 40, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 41, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 42, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 34, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 43, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 44, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21729720\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 18, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid β peptide (Aβ) and the Aβ x-42/Î‘β x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Dis. 2011 Feb;41(2):308-17. doi: 10.1016/j.nbd.2010.09.019. Epub 2010 Oct 1.\", \"reference\": \"20888417\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 47, \"target\": 48, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology (Berl). 1997 May;131(2):130-9\", \"reference\": \"9201800\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology (Berl). 1994 Mar;114(2):200-8\", \"reference\": \"7838908\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 50, \"key\": 0}, {\"relation\": \"causesNoChange\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mol Pharmacol. 2007 Feb;71(2):580-7\", \"reference\": \"17095583\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 51, \"key\": 0}, {\"relation\": \"isA\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience. 2009 May 5;160(2):484-91\", \"reference\": \"19272425\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 52, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 53, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 55, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Pharmacol Sci. 2011;117(1):6-11\", \"reference\": \"21821968\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 54, \"target\": 56, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62\", \"reference\": \"11039729\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 44, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 49, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 50, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochem Soc Trans. 2009 Dec;37(Pt 6):1375-7\", \"reference\": \"19909279\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 57, \"target\": 3, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid-β plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"NervousSystem\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 58, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Glaucoma\"}, \"source\": 59, \"target\": 60, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\", \"MeSHDisease\": \"Alzheimer Disease\"}, \"source\": 59, \"target\": 60, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):9033-46\", \"reference\": \"21969301\"}, \"annotations\": {\"MeSHDisease\": \"Alzheimer Disease\", \"NervousSystem\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 59, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene. 2003 Oct 30;318:113-24\", \"reference\": \"14585504\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 6, \"key\": 1}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 61, \"target\": 6, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 61, \"target\": 3, \"key\": -3}, {\"relation\": \"increases\", \"evidence\": \"Copper Sulfate results in increased expression of GABRA5 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549813\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 63, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Copper Sulfate results in decreased expression of GABRB3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549813\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 64, \"key\": 0}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 63, \"target\": 12, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 64, \"target\": 16, \"key\": -6}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 65, \"target\": 66, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of GABRA3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 65, \"target\": 67, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16000229\"}, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 66, \"target\": 65, \"key\": 0}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 66, \"target\": 11, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 67, \"target\": 10, \"key\": -6}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 68, \"target\": 56, \"key\": -4}]};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The concept of expansion then contraction is commonly called \"opening\" in the domain of image processing. Inference of the central dogma then removal of leaf genes and RNAs is such a standard operation that both steps can be run by [pbt.mutation.opening_on_central_dogma](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.opening_on_central_dogma).\n",
    "\n",
    "### Further Consideration\n",
    "\n",
    "The fact that a subgraph contains more than one connected component probably means that there were errors in the original BEL script. There is an entire module devoted to analyzing the errors produced during compilation called `pbt.summary.error_summary`\n",
    "\n",
    "However, it's also possible that the connections are due to lack of knowledge in the literature. In the curation process for the NeuroMMSig Database, many entitity types were not considered. We've developed an algorithm for inferring additional members of a subgraph, including chemicals that occur as intermediates in biochemical processes, and higher level entities such as biological processes. The set of tools for running the algorithm are avaliable in the `pbt.mutations.subgraph_expansion` submodule (see [pbt.mutation.fill_subgraph](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.fill_subgraph)). "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Expanding on the Periphery\n",
    "\n",
    "In this example, we'll look at the Estrogen Subgraph. The subgraph is enriched with unqualified edges and opened with the central dogma."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "example_subgraph_name = 'Estrogen subgraph'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "subgraph = pbt.selection.get_subgraph_by_annotation(graph, annotation='Subgraph', value=example_subgraph_name)\n",
    "\n",
    "pbt.mutation.enrich_unqualified(graph, subgraph)\n",
    "pbt.mutation.opening_on_central_dogma(subgraph)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: Alzheimer's Disease Model - (Subgraph: Estrogen subgraph)\n",
      "Number of nodes: 27\n",
      "Number of edges: 44\n",
      "Network density: 0.06267806267806268\n",
      "Number weakly connected components: 4\n",
      "Average in-degree: 1.6296296296296295\n",
      "Average out-degree: 1.6296296296296295\n"
     ]
    },
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height) {\n",
       "    const function_colors = {\n",
       "        \"Protein\": \"#1F77B4\",\n",
       "        \"Pathology\": \"#FF7F0E\",\n",
       "        \"BiologicalProcess\": \"#2CA02C\",\n",
       "        \"miRNA\": \"#D62728\",\n",
       "        \"Complex\": \"#9467bd\",\n",
       "        \"Composite\": \"#9467bd\",\n",
       "        \"Reaction\": \"#8c564b\",\n",
       "        \"Gene\": \"#e377c2\",\n",
       "        \"Abundance\": \"#bcbd22\",\n",
       "        \"RNA\": \"#17becf\"\n",
       "    };\n",
       "\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"haorxfzkqegvpmtq\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {\"name\": \"Alzheimer's Disease Model - (Subgraph: Estrogen subgraph)\"}, \"pybel_version\": \"0.4.3.dev0\", \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ESR1\", \"cname\": \"ESR1\", \"id\": [\"Protein\", \"HGNC\", \"ESR1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GSK3B\", \"cname\": \"GSK3B\", \"id\": [\"Protein\", \"HGNC\", \"GSK3B\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"17beta-estradiol\", \"cname\": \"17beta-estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"17beta-estradiol\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Parkinson Disease\", \"cname\": \"Parkinson Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Parkinson Disease\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GSK3B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 9}], \"cname\": \"p(HGNC:GSK3B, pmod(Ph, Ser, 9))\", \"id\": [\"Protein\", \"HGNC\", \"GSK3B\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 9]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CYP3A4\", \"cname\": \"CYP3A4\", \"id\": [\"Protein\", \"HGNC\", \"CYP3A4\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"metabolic process\", \"cname\": \"metabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"metabolic process\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"AR\", \"cname\": \"AR\", \"id\": [\"Protein\", \"HGNC\", \"AR\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Thr\", \"pos\": 231}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Thr, 231))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Thr\", 231]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Thr\", \"pos\": 205}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Thr, 205))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Thr\", 205]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 396}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 396))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 396]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 404}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 404))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 404]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 199}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 199))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 199]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 202}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 202))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 202]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"resveratrol\", \"cname\": \"resveratrol\", \"id\": [\"Abundance\", \"CHEBI\", \"resveratrol\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ESR2\", \"cname\": \"ESR2\", \"id\": [\"Protein\", \"HGNC\", \"ESR2\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:\\\"24-hydroxycholesterol\\\"), p(HGNC:ESR2))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"24-hydroxycholesterol\"], [\"Protein\", \"HGNC\", \"ESR2\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"AADAC\", \"cname\": \"AADAC\", \"id\": [\"Protein\", \"HGNC\", \"AADAC\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PPARG\", \"cname\": \"PPARG\", \"id\": [\"Protein\", \"HGNC\", \"PPARG\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"S100A9\", \"cname\": \"S100A9\", \"id\": [\"Protein\", \"HGNC\", \"S100A9\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"TFF1\", \"cname\": \"TFF1\", \"id\": [\"RNA\", \"HGNC\", \"TFF1\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:\\\"medroxyprogesterone acetate\\\"), p(HGNC:ESR2))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"medroxyprogesterone acetate\"], [\"Protein\", \"HGNC\", \"ESR2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"24-hydroxycholesterol\", \"cname\": \"24-hydroxycholesterol\", \"id\": [\"Abundance\", \"CHEBI\", \"24-hydroxycholesterol\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"medroxyprogesterone acetate\", \"cname\": \"medroxyprogesterone acetate\", \"id\": [\"Abundance\", \"CHEBI\", \"medroxyprogesterone acetate\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"cname\": \"MAPT\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\"]}], \"links\": [{\"relation\": \"association\", \"evidence\": \"Herein, we conducted a meta-analysis to clarify the association between ESR1 polymorphisms and the occurrence of AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurosci Lett. 2014 Jun 27;574:41-6\", \"reference\": \"24857745\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Herein, we conducted a meta-analysis to clarify the association between ESR1 polymorphisms and the occurrence of AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurosci Lett. 2014 Jun 27;574:41-6\", \"reference\": \"24857745\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 1, \"target\": 0, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Eur J Neurol. 1999 Jul;6(4):431-5\", \"reference\": \"10362895\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Dementia\"}, \"source\": 1, \"target\": 4, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Eur J Neurol. 1999 Jul;6(4):431-5\", \"reference\": \"10362895\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Parkinson Disease\"}, \"source\": 1, \"target\": 4, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 8}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 11}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 14}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 17}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 2, \"target\": 5, \"key\": -4}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 10, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 11, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 12, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 13, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 14, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 15, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 5, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Eur J Neurol. 1999 Jul;6(4):431-5\", \"reference\": \"10362895\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Dementia\"}, \"source\": 4, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Eur J Neurol. 1999 Jul;6(4):431-5\", \"reference\": \"10362895\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Parkinson Disease\"}, \"source\": 4, \"target\": 1, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 5, \"target\": 2, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuropsychiatr Dis Treat. 2007 Jun;3(3):303-33\", \"reference\": \"19300564\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 6, \"target\": 7, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Inhibition;Binding;Estradiol directly binds to androgen receptor with percentages of binding affnity of 34+/-1% on 10 mcM concentration.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2897467\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 8, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol results in decreased expression of AADAC mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20106945\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Inhibition;Binding;Estradiol directly binds to androgen receptor with percentages of binding affnity of 34+/-1% on 10 mcM concentration.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2897467\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 8, \"key\": 29}, {\"relation\": \"association\", \"evidence\": \"Activation;Binding;Estradiol cytoplasm physically interacts with ESR2 and increases its activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2033587\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 17, \"key\": 162}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of PPARG protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15964169\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 20, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of S100A9 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19484750\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 21, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11331657\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"resveratrol inhibits the reaction [ESR2 protein binds to CAV1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18296501\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 16, \"target\": 17, \"key\": 12}, {\"relation\": \"association\", \"evidence\": \"Activation;Binding;Estradiol cytoplasm physically interacts with ESR2 and increases its activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2033587\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 17, \"target\": 9, \"key\": 162}, {\"relation\": \"association\", \"evidence\": \"resveratrol inhibits the reaction [ESR2 protein binds to CAV1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18296501\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 17, \"target\": 16, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17873880\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 18, \"target\": 17, \"key\": 2}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 18, \"target\": 17, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 18, \"target\": 24, \"key\": -3}, {\"relation\": \"increases\", \"evidence\": \"Activation;Binding;Medroxyprogesterone acetate intracellular binds to and activates ESR2 .\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"9464360\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 23, \"target\": 17, \"key\": 2}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 23, \"target\": 17, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 23, \"target\": 25, \"key\": -3}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 10, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 11, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 12, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 13, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 14, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 15, \"key\": -4}]};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The nodes along the periphery of this subgraph can be investigated with [pbt.mutation.get_subgraph_peripheral_nodes](). Below, it is used to output which nodes which aren't already in the Estrogen Subgraph, and how many in- and out-edges they have to it."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "pnd = pbt.mutation.get_subgraph_peripheral_nodes(graph, subgraph, node_filters=pbt.filters.exclude_pathology_filter)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Protein', 'HGNC', 'APP', ('frag', (672, 713))) 7 2 7\n",
      "('Protein', 'HGNC', 'CDK5') 1 6 7\n",
      "('Protein', 'HGNC', 'APP') 4 4 6\n",
      "('Protein', 'HGNC', 'MAPT', ('pmod', ('bel', 'Glyco'))) 1 5 6\n",
      "('Abundance', 'CHEBI', 'simvastatin') 3 5 5\n",
      "('Abundance', 'CHEBI', 'hydrogen peroxide') 2 4 4\n",
      "('Abundance', 'CHEBI', 'raloxifene') 2 4 4\n",
      "('Protein', 'HGNC', 'CREBBP') 4 3 4\n",
      "('Abundance', 'CHEBI', 'mifepristone') 1 4 4\n",
      "('Protein', 'HGNC', 'FOXO1') 4 4 4\n",
      "('Protein', 'HGNC', 'CASP3') 4 2 4\n",
      "('Protein', 'HGNC', 'CTNNB1') 3 2 4\n",
      "('Protein', 'HGNC', 'MAPK14') 1 3 4\n",
      "('Protein', 'HGNC', 'TNF') 4 2 4\n",
      "('Protein', 'HGNC', 'LEP') 2 2 4\n"
     ]
    }
   ],
   "source": [
    "for node in sorted(pnd, key=lambda k: len(set(pnd[k]['successor']) | set(pnd[k]['predecessor'])), reverse=True):\n",
    "    pred_d = pnd[node]['predecessor']\n",
    "    succ_d = pnd[node]['successor']\n",
    "\n",
    "    if 0 == len(pred_d) or 0 == len(succ_d):\n",
    "        continue\n",
    "    \n",
    "    periphery = set(pred_d) | set(succ_d)\n",
    "    \n",
    "    if 4 > len(periphery):\n",
    "        continue\n",
    "    \n",
    "    print(node, len(pred_d), len(succ_d), len(periphery))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The function [pbt.mutation.expand_periphery](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.expand_periphery) automatically handles these calcuations and allows for the specification of a threshold for how \"confident\" it should be to add a node to the subgraph. Filters to exclude pathologies (which have many connections to everything). The inferred edges are limited to only causal edges, to avoid adding many low confidence relations. Luckily, the Estrogen Subgraph is small and doesn't become unmanagable after expanding along the periphery. Other, larger subgraphs might have this issue. If the subgraph becomes too complicated, it might be useful to extract the causal subgraph using  [pbt.selection.get_causal_subgraph](http://pybel-tools.readthedocs.io/en/latest/selection.html#pybel_tools.selection.get_causal_subgraph)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "pbt.mutation.expand_periphery(\n",
    "    graph, \n",
    "    subgraph, \n",
    "    node_filters=pbt.filters.exclude_pathology_filter, \n",
    "    edge_filters=pbt.filters.keep_causal_edges,\n",
    "    threshold=3)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "collapsed": false,
    "deletable": true,
    "editable": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Name: Alzheimer's Disease Model - (Subgraph: Estrogen subgraph)\n",
      "Number of nodes: 52\n",
      "Number of edges: 764\n",
      "Network density: 0.28808446455505277\n",
      "Number weakly connected components: 1\n",
      "Average in-degree: 14.692307692307692\n",
      "Average out-degree: 14.692307692307692\n"
     ]
    },
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height) {\n",
       "    const function_colors = {\n",
       "        \"Protein\": \"#1F77B4\",\n",
       "        \"Pathology\": \"#FF7F0E\",\n",
       "        \"BiologicalProcess\": \"#2CA02C\",\n",
       "        \"miRNA\": \"#D62728\",\n",
       "        \"Complex\": \"#9467bd\",\n",
       "        \"Composite\": \"#9467bd\",\n",
       "        \"Reaction\": \"#8c564b\",\n",
       "        \"Gene\": \"#e377c2\",\n",
       "        \"Abundance\": \"#bcbd22\",\n",
       "        \"RNA\": \"#17becf\"\n",
       "    };\n",
       "\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"fqvbzxtshepyqgcu\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {\"name\": \"Alzheimer's Disease Model - (Subgraph: Estrogen subgraph)\"}, \"pybel_version\": \"0.4.3.dev0\", \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ESR1\", \"cname\": \"ESR1\", \"id\": [\"Protein\", \"HGNC\", \"ESR1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GSK3B\", \"cname\": \"GSK3B\", \"id\": [\"Protein\", \"HGNC\", \"GSK3B\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"17beta-estradiol\", \"cname\": \"17beta-estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"17beta-estradiol\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Parkinson Disease\", \"cname\": \"Parkinson Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Parkinson Disease\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GSK3B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 9}], \"cname\": \"p(HGNC:GSK3B, pmod(Ph, Ser, 9))\", \"id\": [\"Protein\", \"HGNC\", \"GSK3B\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 9]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CYP3A4\", \"cname\": \"CYP3A4\", \"id\": [\"Protein\", \"HGNC\", \"CYP3A4\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"metabolic process\", \"cname\": \"metabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"metabolic process\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"AR\", \"cname\": \"AR\", \"id\": [\"Protein\", \"HGNC\", \"AR\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Thr\", \"pos\": 231}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Thr, 231))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Thr\", 231]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Thr\", \"pos\": 205}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Thr, 205))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Thr\", 205]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 396}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 396))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 396]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 404}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 404))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 404]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 199}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 199))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 199]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 202}], \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 202))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 202]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"resveratrol\", \"cname\": \"resveratrol\", \"id\": [\"Abundance\", \"CHEBI\", \"resveratrol\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ESR2\", \"cname\": \"ESR2\", \"id\": [\"Protein\", \"HGNC\", \"ESR2\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:\\\"24-hydroxycholesterol\\\"), p(HGNC:ESR2))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"24-hydroxycholesterol\"], [\"Protein\", \"HGNC\", \"ESR2\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"AADAC\", \"cname\": \"AADAC\", \"id\": [\"Protein\", \"HGNC\", \"AADAC\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PPARG\", \"cname\": \"PPARG\", \"id\": [\"Protein\", \"HGNC\", \"PPARG\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"S100A9\", \"cname\": \"S100A9\", \"id\": [\"Protein\", \"HGNC\", \"S100A9\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"TFF1\", \"cname\": \"TFF1\", \"id\": [\"RNA\", \"HGNC\", \"TFF1\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:\\\"medroxyprogesterone acetate\\\"), p(HGNC:ESR2))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"medroxyprogesterone acetate\"], [\"Protein\", \"HGNC\", \"ESR2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"24-hydroxycholesterol\", \"cname\": \"24-hydroxycholesterol\", \"id\": [\"Abundance\", \"CHEBI\", \"24-hydroxycholesterol\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"medroxyprogesterone acetate\", \"cname\": \"medroxyprogesterone acetate\", \"id\": [\"Abundance\", \"CHEBI\", \"medroxyprogesterone acetate\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"cname\": \"MAPT\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CXCL10\", \"cname\": \"CXCL10\", \"id\": [\"Protein\", \"HGNC\", \"CXCL10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ABCA1\", \"cname\": \"ABCA1\", \"id\": [\"Protein\", \"HGNC\", \"ABCA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"HSPA1B\", \"cname\": \"HSPA1B\", \"id\": [\"Protein\", \"HGNC\", \"HSPA1B\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"IL1B\", \"cname\": \"IL1B\", \"id\": [\"Protein\", \"HGNC\", \"IL1B\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"IL6\", \"cname\": \"IL6\", \"id\": [\"Protein\", \"HGNC\", \"IL6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPK14\", \"cname\": \"MAPK14\", \"id\": [\"Protein\", \"HGNC\", \"MAPK14\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"NOS3\", \"cname\": \"NOS3\", \"id\": [\"Protein\", \"HGNC\", \"NOS3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"VCAM1\", \"cname\": \"VCAM1\", \"id\": [\"Protein\", \"HGNC\", \"VCAM1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"VEGFA\", \"cname\": \"VEGFA\", \"id\": [\"Protein\", \"HGNC\", \"VEGFA\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"F2\", \"cname\": \"F2\", \"id\": [\"Protein\", \"HGNC\", \"F2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"LEP\", \"cname\": \"LEP\", \"id\": [\"Protein\", \"HGNC\", \"LEP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"NOS2\", \"cname\": \"NOS2\", \"id\": [\"Protein\", \"HGNC\", \"NOS2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TGFBR2\", \"cname\": \"TGFBR2\", \"id\": [\"Protein\", \"HGNC\", \"TGFBR2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"DYRK1A\", \"cname\": \"DYRK1A\", \"id\": [\"Protein\", \"HGNC\", \"DYRK1A\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CDK5\", \"cname\": \"CDK5\", \"id\": [\"Protein\", \"HGNC\", \"CDK5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CTNNB1\", \"cname\": \"CTNNB1\", \"id\": [\"Protein\", \"HGNC\", \"CTNNB1\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"curcumin\", \"cname\": \"curcumin\", \"id\": [\"Abundance\", \"CHEBI\", \"curcumin\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"mifepristone\", \"cname\": \"mifepristone\", \"id\": [\"Abundance\", \"CHEBI\", \"mifepristone\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"raloxifene\", \"cname\": \"raloxifene\", \"id\": [\"Abundance\", \"CHEBI\", \"raloxifene\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Glyco\"}}], \"cname\": \"p(HGNC:MAPT, pmod(Glyco))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Glyco\"]]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"celecoxib\", \"cname\": \"celecoxib\", \"id\": [\"Abundance\", \"CHEBI\", \"celecoxib\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"rosiglitazone\", \"cname\": \"rosiglitazone\", \"id\": [\"Abundance\", \"CHEBI\", \"rosiglitazone\"]}, {\"function\": \"Abundance\", \"namespace\": \"SCHEM\", \"name\": \"Calyculin A\", \"cname\": \"Calyculin A\", \"id\": [\"Abundance\", \"SCHEM\", \"Calyculin A\"]}], \"links\": [{\"relation\": \"association\", \"evidence\": \"Herein, we conducted a meta-analysis to clarify the association between ESR1 polymorphisms and the occurrence of AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurosci Lett. 2014 Jun 27;574:41-6\", \"reference\": \"24857745\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Herein, we conducted a meta-analysis to clarify the association between ESR1 polymorphisms and the occurrence of AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurosci Lett. 2014 Jun 27;574:41-6\", \"reference\": \"24857745\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 1, \"target\": 0, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Eur J Neurol. 1999 Jul;6(4):431-5\", \"reference\": \"10362895\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Dementia\"}, \"source\": 1, \"target\": 4, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Eur J Neurol. 1999 Jul;6(4):431-5\", \"reference\": \"10362895\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Parkinson Disease\"}, \"source\": 1, \"target\": 4, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 8}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 11}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 14}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 17}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 2, \"target\": 5, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7\", \"reference\": \"20056834\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Condition\": \"Normal Healthy State\", \"Subgraph\": \"GSK3 subgraph\"}, \"source\": 2, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7\", \"reference\": \"20056834\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Condition\": \"Normal Healthy State\", \"Subgraph\": \"Chemokine signaling subgraph\"}, \"source\": 2, \"target\": 27, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Rev Neurosci. 2011 Dec 21;23(1):1-11. doi: 10.1515/rns.2011.061.\", \"reference\": \"22718609\"}, \"subject\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 2, \"target\": 28, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The inhibition of this kinase can prevent the aggregation of β-amyloid (Aβ) and hyperphosphorylation of tau protein.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Rev Neurosci. 2011 Dec 21;23(1):1-11. doi: 10.1515/rns.2011.061.\", \"reference\": \"22718609\"}, \"subject\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 2, \"target\": 28, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 10, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 11, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 12, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 13, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 14, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 15, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 5, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Eur J Neurol. 1999 Jul;6(4):431-5\", \"reference\": \"10362895\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Dementia\"}, \"source\": 4, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Eur J Neurol. 1999 Jul;6(4):431-5\", \"reference\": \"10362895\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Parkinson Disease\"}, \"source\": 4, \"target\": 1, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neural Transmission2008\", \"reference\": \"18217188\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 5, \"target\": 2, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuropsychiatr Dis Treat. 2007 Jun;3(3):303-33\", \"reference\": \"19300564\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 6, \"target\": 7, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Inhibition;Binding;Estradiol directly binds to androgen receptor with percentages of binding affnity of 34+/-1% on 10 mcM concentration.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2897467\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 8, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol results in decreased expression of AADAC mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20106945\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Inhibition;Binding;Estradiol directly binds to androgen receptor with percentages of binding affnity of 34+/-1% on 10 mcM concentration.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2897467\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 8, \"key\": 29}, {\"relation\": \"association\", \"evidence\": \"Activation;Binding;Estradiol cytoplasm physically interacts with ESR2 and increases its activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2033587\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 17, \"key\": 162}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of PPARG protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15964169\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 20, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of S100A9 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19484750\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 21, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11331657\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 9, \"target\": 22, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of CXCL10 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15557169\"}, \"annotations\": {}, \"source\": 9, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of CXCL10 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17404688\"}, \"annotations\": {}, \"source\": 9, \"target\": 27, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of CXCL10 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19533603\"}, \"annotations\": {}, \"source\": 9, \"target\": 27, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol results in decreased expression of ABCA1 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20106945\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 9, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of HSPA1B mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20106945\"}, \"annotations\": {}, \"source\": 9, \"target\": 30, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of HSPA1B mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12927369\"}, \"annotations\": {}, \"source\": 9, \"target\": 30, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16298037\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16934544\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17266178\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17636213\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20600708\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20621171\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22219637\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12072388\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21501669\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17068060\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21127968\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"bisphenol A inhibits the reaction [Estradiol inhibits the reaction [IL1B protein results in increased expression of MMP1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16298037\"}, \"annotations\": {}, \"source\": 9, \"target\": 31, \"key\": 11}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10731640\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15528032\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15983630\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16298037\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17266178\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17532054\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19401270\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20404318\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20621171\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12538720\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17615358\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19533603\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 11}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21501669\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"chromic chloride promotes the reaction [Estradiol inhibits the reaction [Glucose results in increased secretion of IL6 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21277368\"}, \"annotations\": {}, \"source\": 9, \"target\": 32, \"key\": 13}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased activity of MAPK14 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15955695\"}, \"annotations\": {}, \"source\": 9, \"target\": 33, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15956360\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15615701\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11583108\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14742696\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15358673\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16840783\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18296501\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21513769\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17873880\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18628394\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12020746\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16436525\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 11}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11583108\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11779577\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 13}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12810170\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 14}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15358673\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 15}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21092740\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 16}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15653758\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 17}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15967841\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 18}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16680078\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 19}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17618301\"}, \"annotations\": {}, \"source\": 9, \"target\": 34, \"key\": 20}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12547825\"}, \"annotations\": {}, \"source\": 9, \"target\": 35, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17578864\"}, \"annotations\": {}, \"source\": 9, \"target\": 35, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19553526\"}, \"annotations\": {}, \"source\": 9, \"target\": 35, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16807025\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17275223\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16299233\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17289903\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18252963\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19148513\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19167446\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 6}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19828145\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 7}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19838210\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 8}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11985600\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 9}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15591033\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 10}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15598610\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 11}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17640349\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 12}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19693291\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 13}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20025956\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 14}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15774498\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 15}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12810170\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 16}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20732338\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 17}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21277368\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 18}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"8344219\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 19}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"9214597\"}, \"annotations\": {}, \"source\": 9, \"target\": 36, \"key\": 20}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12182891\"}, \"annotations\": {}, \"source\": 9, \"target\": 37, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12963085\"}, \"annotations\": {}, \"source\": 9, \"target\": 37, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol inhibits the reaction [APP protein results in increased activity of CASP3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22467019\"}, \"annotations\": {}, \"source\": 9, \"target\": 37, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Estradiol results in decreased expression of F2 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"23373633\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 9, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of LEP mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18359623\"}, \"annotations\": {}, \"source\": 9, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of LEP mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"23153703\"}, \"annotations\": {}, \"source\": 9, \"target\": 39, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17873880\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11583108\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11063824\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15256495\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17873880\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21512103\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12020746\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17068060\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11583108\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12810170\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16006544\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17053178\"}, \"annotations\": {}, \"source\": 9, \"target\": 40, \"key\": 11}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of TGFBR2 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19484750\"}, \"annotations\": {}, \"source\": 9, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of TGFBR2 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"7585526\"}, \"annotations\": {}, \"source\": 9, \"target\": 41, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Akt subgraph\"}, \"source\": 10, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Sphingolipid metabolic subgraph\"}, \"source\": 10, \"target\": 28, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 10, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Akt subgraph\"}, \"source\": 12, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Sphingolipid metabolic subgraph\"}, \"source\": 12, \"target\": 28, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 12, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Akt subgraph\"}, \"source\": 13, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Sphingolipid metabolic subgraph\"}, \"source\": 13, \"target\": 28, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include ÃŸ-amyloid protein (AÃŸ) generation and tau phosphorylation. In particular, AMPK may regulate AÃŸ generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating AÃŸ generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of AÃŸ. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including AÃŸ generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular Med. 2012 Mar;14(1):1-14. Epub 2012 Feb 26.\", \"reference\": \"22367557\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 13, \"target\": 28, \"key\": 2}, {\"relation\": \"association\", \"evidence\": \"resveratrol inhibits the reaction [ESR2 protein binds to CAV1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18296501\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 16, \"target\": 17, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21189227\"}, \"annotations\": {}, \"source\": 16, \"target\": 27, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21967610\"}, \"annotations\": {}, \"source\": 16, \"target\": 27, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21756928\"}, \"annotations\": {}, \"source\": 16, \"target\": 27, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21967610\"}, \"annotations\": {}, \"source\": 16, \"target\": 27, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21189227\"}, \"annotations\": {}, \"source\": 16, \"target\": 27, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21807089\"}, \"annotations\": {}, \"source\": 16, \"target\": 27, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"2-chloro-5-nitrobenzanilide inhibits the reaction [resveratrol results in increased expression of ABCA1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16901463\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 16, \"target\": 29, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"2-chloro-5-nitrobenzanilide inhibits the reaction [resveratrol results in increased expression of ABCA1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20372816\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 16, \"target\": 29, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"2-chloro-5-nitrobenzanilide inhibits the reaction [resveratrol results in increased expression of ABCA1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"23041272\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 16, \"target\": 29, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"resveratrol results in increased expression of HSPA1B mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17956190\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 16, \"target\": 30, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15135313\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18606398\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19008341\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19375465\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19889203\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20943792\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22138609\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19011540\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10496962\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12689943\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12871381\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15135313\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 11}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15180920\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16338976\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 13}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17191021\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 14}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17388968\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 15}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17404069\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 16}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17959154\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 17}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18377686\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 18}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18759268\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 19}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18776171\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 20}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19284563\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 21}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19346296\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 22}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19751497\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 23}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20426787\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 24}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20531350\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 25}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20816778\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 26}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21211511\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 27}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21289251\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 28}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22549761\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 29}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"9974427\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 30}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15652768\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 31}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17690738\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 32}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18549505\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 33}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19284563\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 34}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19346296\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 35}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19689081\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 36}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19940103\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 37}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20132809\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 38}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20712904\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 39}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21284090\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 40}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21807089\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 41}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22069489\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 42}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22118570\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 43}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22363816\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 44}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22698256\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 45}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22952890\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 46}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11376495\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 47}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15734790\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 48}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15971681\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 49}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17035056\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 50}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17481685\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 51}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18424637\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 52}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19228061\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 53}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20036306\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 54}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20050970\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 55}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20307516\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 56}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20422370\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 57}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21111721\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 58}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21439372\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 59}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22246136\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 60}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL1B protein results in decreased abundance of Proteoglycans]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22713680\"}, \"annotations\": {}, \"source\": 16, \"target\": 31, \"key\": 61}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15135313\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18549505\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19373235\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20943792\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16150460\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15135313\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16490592\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16973825\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17164350\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17388968\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18209571\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18776171\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 11}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19284563\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19346296\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 13}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19416633\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 14}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20463039\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 15}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20531350\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 16}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20578705\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 17}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20816778\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 18}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20844277\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 19}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21371465\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 20}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21756928\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 21}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22493042\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 22}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19063842\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 23}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15652768\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 24}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16813520\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 25}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17374693\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 26}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17630201\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 27}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17690738\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 28}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17967414\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 29}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18549505\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 30}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19014921\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 31}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19063842\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 32}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19284563\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 33}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19346296\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 34}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19689081\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 35}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19940103\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 36}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20188786\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 37}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20712904\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 38}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20730501\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 39}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21807089\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 40}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22069489\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 41}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22118570\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 42}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22698256\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 43}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11108930\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 44}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15734790\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 45}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15971681\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 46}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17035056\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 47}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17481685\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 48}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18424637\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 49}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20036306\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 50}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20117814\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 51}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20211601\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 52}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20307516\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 53}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21192278\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 54}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21439372\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 55}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22471748\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 56}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [IL6 protein results in increased expression of ICAM1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22713680\"}, \"annotations\": {}, \"source\": 16, \"target\": 32, \"key\": 57}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15615701\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16150460\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20978231\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12270858\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15740983\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16759640\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16775512\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17052855\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17278969\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17499741\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18234130\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18296501\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 11}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18716157\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19815564\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 13}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19846903\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 14}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20021702\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 15}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20706672\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 16}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20878097\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 17}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20960276\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 18}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21791144\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 19}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22314268\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 20}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22358095\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 21}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19066340\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 22}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19478208\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 23}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20067468\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 24}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20610621\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 25}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20675566\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 26}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22552115\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 27}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22610192\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 28}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14990356\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 29}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16775512\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 30}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17188708\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 31}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17600658\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 32}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18266981\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 33}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20564508\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 34}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21666113\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 35}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [resveratrol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22191573\"}, \"annotations\": {}, \"source\": 16, \"target\": 34, \"key\": 36}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20709957\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12615669\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17586618\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21371465\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"9846848\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18611391\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15734790\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20709957\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22029500\"}, \"annotations\": {}, \"source\": 16, \"target\": 35, \"key\": 8}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14573751\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15297429\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18606398\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19889203\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22197494\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22314268\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15297429\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 6}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16198371\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 7}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16227395\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 8}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16490592\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 9}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16580641\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 10}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16973825\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 11}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17473185\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 12}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17919812\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 13}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17935668\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 14}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17992120\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 15}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18674879\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 16}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20012470\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 17}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20021702\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 18}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20578705\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 19}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20696143\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 20}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20801891\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 21}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21209944\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 22}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22314268\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 23}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18572362\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 24}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21086752\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 25}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21530968\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 26}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22058332\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 27}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16198371\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 28}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17188708\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 29}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22050707\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 30}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22191573\"}, \"annotations\": {}, \"source\": 16, \"target\": 36, \"key\": 31}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22138609\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16162502\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16212921\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17597573\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20080969\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16162502\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20080969\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22118570\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15134381\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16183991\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in decreased expression of APP protein modified form]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16685418\"}, \"annotations\": {}, \"source\": 16, \"target\": 37, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15342215\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 16, \"target\": 38, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16051184\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 16, \"target\": 38, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol results in decreased expression of LEP mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21713995\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 16, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14982945\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19008341\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20828608\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21189227\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21612158\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22857612\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12060119\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 6}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19549798\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 7}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19846903\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 8}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20706672\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 9}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22251620\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 10}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10086329\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 11}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10188978\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 12}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10370867\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 13}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11020457\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 14}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12003803\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 15}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12175900\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 16}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14623172\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 17}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15589480\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 18}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16116226\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 19}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16183991\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 20}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18551458\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 21}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19066340\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 22}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20132809\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 23}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20155626\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 24}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20527891\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 25}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20675566\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 26}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20712904\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 27}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21189227\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 28}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21284090\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 29}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21355597\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 30}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21945106\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 31}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22069489\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 32}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22118570\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 33}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22363816\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 34}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22610192\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 35}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22698256\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 36}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22952890\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 37}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14982945\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 38}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14990356\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 39}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16178859\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 40}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16366677\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 41}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16389574\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 42}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16685418\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 43}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17416599\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 44}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17600658\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 45}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17651055\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 46}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17666920\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 47}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17923197\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 48}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18424637\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 49}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18513711\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 50}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18812229\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 51}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19228061\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 52}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19796704\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 53}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20422370\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 54}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20501860\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 55}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20564508\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 56}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20828608\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 57}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21914476\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 58}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"9581680\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 59}, {\"relation\": \"increases\", \"evidence\": \"Capsaicin promotes the reaction [resveratrol results in increased expression of NOS2 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20825639\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 60}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [TNF protein results in increased expression of NOS2A mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16973825\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 61}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [TNF protein results in increased expression of NOS2A mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17052855\"}, \"annotations\": {}, \"source\": 16, \"target\": 40, \"key\": 62}, {\"relation\": \"increases\", \"evidence\": \"resveratrol results in increased expression of TGFBR2 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20637737\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 16, \"target\": 41, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol results in decreased expression of DYRK1A mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12569576\"}, \"annotations\": {}, \"source\": 16, \"target\": 42, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [TNF protein results in increased activity of CDK5 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21736731\"}, \"annotations\": {}, \"source\": 16, \"target\": 43, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"resveratrol inhibits the reaction [TNF protein results in increased activity of CDK5 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21736731\"}, \"annotations\": {}, \"source\": 16, \"target\": 43, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14573751\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19665018\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11895924\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18347188\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19047049\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20696143\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22245592\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 6}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22314268\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 7}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22935447\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 8}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19665018\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 9}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20542495\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 10}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22935447\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 11}, {\"relation\": \"increases\", \"evidence\": \"CTNNB1 protein promotes the reaction [resveratrol results in increased expression of VEGFA protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17188708\"}, \"annotations\": {}, \"source\": 16, \"target\": 44, \"key\": 12}, {\"relation\": \"association\", \"evidence\": \"Activation;Binding;Estradiol cytoplasm physically interacts with ESR2 and increases its activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2033587\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 17, \"target\": 9, \"key\": 162}, {\"relation\": \"association\", \"evidence\": \"resveratrol inhibits the reaction [ESR2 protein binds to CAV1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18296501\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 17, \"target\": 16, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17873880\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 18, \"target\": 17, \"key\": 2}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 18, \"target\": 17, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 18, \"target\": 24, \"key\": -3}, {\"relation\": \"decreases\", \"evidence\": \"The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (Aβ) production through promoting cholesterol efflux from glial cells. PPAR-γ agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) ε4 allele\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Aging. 2011 Mar;32(3):547.e1-6. Epub 2009 Aug 6.\", \"reference\": \"19660836\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 28, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (Aβ) production through promoting cholesterol efflux from glial cells. PPAR-γ agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) ε4 allele\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Aging. 2011 Mar;32(3):547.e1-6. Epub 2009 Aug 6.\", \"reference\": \"19660836\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 20, \"target\": 28, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Medical Hypotheses2006\", \"reference\": \"16828233\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 28, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Medical Hypotheses2006\", \"reference\": \"16828233\"}, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 20, \"target\": 28, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (Aβ) production through promoting cholesterol efflux from glial cells. PPAR-γ agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) ε4 allele\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Aging. 2011 Mar;32(3):547.e1-6. Epub 2009 Aug 6.\", \"reference\": \"19660836\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 28, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (Aβ) production through promoting cholesterol efflux from glial cells. PPAR-γ agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) ε4 allele\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Aging. 2011 Mar;32(3):547.e1-6. Epub 2009 Aug 6.\", \"reference\": \"19660836\"}, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 20, \"target\": 28, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Medical Hypotheses2006\", \"reference\": \"16828233\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 28, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Medical Hypotheses2006\", \"reference\": \"16828233\"}, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 20, \"target\": 28, \"key\": 7}, {\"relation\": \"increases\", \"evidence\": \"As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.\", \"reference\": \"20164187\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.\", \"reference\": \"20164187\"}, \"annotations\": {\"Subgraph\": \"Interleukin signaling subgraph\"}, \"source\": 20, \"target\": 32, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.\", \"reference\": \"20164187\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 32, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"As RNA stability is often regulated via 3'-untranslated regions (UTRs), we analyzed the impact of the PPARgamma-3'-UTR by reporter assays using specific constructs. LPS significantly reduced luciferase activity of the pGL3-PPARgamma-3'-UTR, suggesting that PPARgamma1 mRNA is destabilized. Deletion or mutation of a potential microRNA-27a/b (miR-27a/b) binding site within the 3'-UTR restored luciferase activity. Moreover, inhibition of miR-27b, which was induced upon LPS exposure, partially reversed PPARgamma1 mRNA decay, whereas miR-27b overexpression decreased PPARgamma1 mRNA content. In addition, LPS further reduced this decay. The functional relevance of miR-27b-dependent PPARgamma1 decrease was proven by inhibition or overexpression of miR-27b, which affected LPS-induced expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFalpha) and interleukin (IL)-6. We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.\", \"reference\": \"20164187\"}, \"annotations\": {\"Subgraph\": \"Interleukin signaling subgraph\"}, \"source\": 20, \"target\": 32, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"During differentiation of macrophages primarily the promoter 3 and to a certain extent promoter 1 is activated. Consequently macrophages mainly express PPARγ1 (10). In macrophages PPARγ represses inducible nitric-oxide (NO) synthase induction as well as concomitant NO production (11) and attenuates the oxidative burst (13, 14). Moreover, inhibiting nuclear factor ÎºB (NFÎºB) decreases expression of inflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor Î± (TNFÎ±) or IL-6 (12). Thus, PPARγ is important to shape an anti-inflammatory macrophage phenotype and appears crucial for dampening inflammation\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.\", \"reference\": \"20164187\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 40, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Recently, it was proposed that some NSAIDs might activate the peroxisome proliferator-activated / receptor-gamma (PPAR-gamma). PPAR-gamma belongs to a family of nuclear receptors that are able to regulate the / transcription of pro-inflammatory molecules, such as iNOS. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Int J Dev Neurosci. 2006 Apr-May;24(2-3):167-76. Epub 2006 Feb 10.\", \"reference\": \"16472958\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 40, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Recently, it was proposed that some NSAIDs might activate the peroxisome proliferator-activated / receptor-gamma (PPAR-gamma). PPAR-gamma belongs to a family of nuclear receptors that are able to regulate the / transcription of pro-inflammatory molecules, such as iNOS. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Int J Dev Neurosci. 2006 Apr-May;24(2-3):167-76. Epub 2006 Feb 10.\", \"reference\": \"16472958\"}, \"annotations\": {\"Subgraph\": \"Nitric oxide subgraph\"}, \"source\": 20, \"target\": 40, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"During differentiation of macrophages primarily the promoter 3 and to a certain extent promoter 1 is activated. Consequently macrophages mainly express PPARγ1 (10). In macrophages PPARγ represses inducible nitric-oxide (NO) synthase induction as well as concomitant NO production (11) and attenuates the oxidative burst (13, 14). Moreover, inhibiting nuclear factor ÎºB (NFÎºB) decreases expression of inflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor Î± (TNFÎ±) or IL-6 (12). Thus, PPARγ is important to shape an anti-inflammatory macrophage phenotype and appears crucial for dampening inflammation\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.\", \"reference\": \"20164187\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 40, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"During differentiation of macrophages primarily the promoter 3 and to a certain extent promoter 1 is activated. Consequently macrophages mainly express PPARγ1 (10). In macrophages PPARγ represses inducible nitric-oxide (NO) synthase induction as well as concomitant NO production (11) and attenuates the oxidative burst (13, 14). Moreover, inhibiting nuclear factor ÎºB (NFÎºB) decreases expression of inflammatory cytokines such as interleukin (IL)-1, tumor necrosis factor Î± (TNFÎ±) or IL-6 (12). Thus, PPARγ is important to shape an anti-inflammatory macrophage phenotype and appears crucial for dampening inflammation\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem. 2010 Apr 16;285(16):11846-53. doi: 10.1074/jbc.M109.066399. Epub 2010 Feb 17.\", \"reference\": \"20164187\"}, \"annotations\": {\"Subgraph\": \"Nitric oxide subgraph\"}, \"source\": 20, \"target\": 40, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPARγ leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against Aβ neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in β-catenin and inhibition of GSK-3β is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPARγ by a potent ligand leads to β-catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPARγ activation in neuroprotection, PPARγ agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPARγ activation . A recent report demonstrates that overexpression of PPARγ in cultured cells leads to a dramatic decrease in the production of Aβ, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing Aβ secretion, PPARγ protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.\", \"reference\": \"19885299\"}, \"subject\": {\"modifier\": \"Activity\"}, \"object\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 20, \"target\": 44, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPARγ leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against Aβ neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in β-catenin and inhibition of GSK-3β is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPARγ by a potent ligand leads to β-catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPARγ activation in neuroprotection, PPARγ agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPARγ activation . A recent report demonstrates that overexpression of PPARγ in cultured cells leads to a dramatic decrease in the production of Aβ, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing Aβ secretion, PPARγ protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):508-16.\", \"reference\": \"19885299\"}, \"subject\": {\"modifier\": \"Activity\"}, \"object\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"Beta-Catenin subgraph\"}, \"source\": 20, \"target\": 44, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"In CAA, and probably in AD, corticosteroid treatment suppresses the secondarily induced vascular inflammation (Chang et al., 2012, Kloppenborg et al., 2010 and Machida et al., 2012) and the activation of S100A9/Mrp14 (Gebhardt et al., 2002 and Kametani and Ikeda, 2013). Recently, it has been reported that anti-Aβ autoantibodies were progressively reduced in the cerebrospinal fluid of a patient with CAA-related inflammation, following intravenous steroid administration (Piazza et al., 2013). Reduction of S100A9/Mrp14 might induce suppression of amyloid fibril formation (Zhang et al., 2012) and increase phagocytosis of fibrillar Aβ in microglia cells (Kummer et al., 2012), resulting in reduced Aβ amyloid fibril deposition.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Aging. 2014 Apr;35(4):e11-2\", \"reference\": \"24262203\"}, \"annotations\": {\"Subgraph\": \"Inflammatory response subgraph\"}, \"source\": 21, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In CAA, and probably in AD, corticosteroid treatment suppresses the secondarily induced vascular inflammation (Chang et al., 2012, Kloppenborg et al., 2010 and Machida et al., 2012) and the activation of S100A9/Mrp14 (Gebhardt et al., 2002 and Kametani and Ikeda, 2013). Recently, it has been reported that anti-Aβ autoantibodies were progressively reduced in the cerebrospinal fluid of a patient with CAA-related inflammation, following intravenous steroid administration (Piazza et al., 2013). Reduction of S100A9/Mrp14 might induce suppression of amyloid fibril formation (Zhang et al., 2012) and increase phagocytosis of fibrillar Aβ in microglia cells (Kummer et al., 2012), resulting in reduced Aβ amyloid fibril deposition.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Aging. 2014 Apr;35(4):e11-2\", \"reference\": \"24262203\"}, \"annotations\": {\"Subgraph\": \"Metabolism of steroid hormones subgraph\"}, \"source\": 21, \"target\": 28, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with Aβ.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Acta Neuropathol. 2014 Apr;127(4):507-22\", \"reference\": \"24240735\"}, \"annotations\": {\"Subgraph\": \"Toll like receptor subgraph\"}, \"source\": 21, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with Aβ.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Acta Neuropathol. 2014 Apr;127(4):507-22\", \"reference\": \"24240735\"}, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 21, \"target\": 28, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We therefore conclude that Mrp14 promotes APP processing and Aβ accumulation under neuroinflammatory conditions.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Neurosci. 2012 Dec 5;32(49):17824-9.\", \"reference\": \"23223301\"}, \"annotations\": {\"Subgraph\": \"Toll like receptor subgraph\"}, \"source\": 21, \"target\": 28, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"We therefore conclude that Mrp14 promotes APP processing and Aβ accumulation under neuroinflammatory conditions.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Neurosci. 2012 Dec 5;32(49):17824-9.\", \"reference\": \"23223301\"}, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 21, \"target\": 28, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"Activation;Binding;Medroxyprogesterone acetate intracellular binds to and activates ESR2 .\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"9464360\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 23, \"target\": 17, \"key\": 2}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 23, \"target\": 17, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 23, \"target\": 25, \"key\": -3}, {\"relation\": \"increases\", \"evidence\": \"24-hydroxycholesterol results in increased expression of ABCA1 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15148325\"}, \"annotations\": {}, \"source\": 24, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"24-hydroxycholesterol results in increased expression of ABCA1 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19126211\"}, \"annotations\": {}, \"source\": 24, \"target\": 29, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"24-hydroxycholesterol results in increased expression of ABCA1 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16530456\"}, \"annotations\": {}, \"source\": 24, \"target\": 29, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate results in decreased expression of IL1B mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20843944\"}, \"annotations\": {}, \"source\": 25, \"target\": 31, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate results in decreased expression of IL1B mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16537180\"}, \"annotations\": {}, \"source\": 25, \"target\": 31, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate results in decreased expression of IL6 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16702388\"}, \"annotations\": {}, \"source\": 25, \"target\": 32, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate results in decreased expression of IL6 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20843944\"}, \"annotations\": {}, \"source\": 25, \"target\": 32, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate results in decreased expression of IL6 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16537180\"}, \"annotations\": {}, \"source\": 25, \"target\": 32, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15358673\"}, \"annotations\": {}, \"source\": 25, \"target\": 34, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased activity of NOS3 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15358673\"}, \"annotations\": {}, \"source\": 25, \"target\": 34, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15358673\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 25, \"target\": 35, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Medroxyprogesterone Acetate results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15860260\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 25, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Medroxyprogesterone Acetate results in increased expression of VEGFA mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17010073\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 25, \"target\": 36, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Medroxyprogesterone Acetate promotes the reaction [F2 protein results in increased expression of F3 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11733402\"}, \"annotations\": {}, \"source\": 25, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Medroxyprogesterone Acetate promotes the reaction [F2 protein results in increased expression of F3 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"1828463\"}, \"annotations\": {}, \"source\": 25, \"target\": 38, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Medroxyprogesterone Acetate promotes the reaction [F2 protein results in increased expression of F3 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11733402\"}, \"annotations\": {}, \"source\": 25, \"target\": 38, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Medroxyprogesterone Acetate results in increased expression of TGFBR2 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20843944\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 25, \"target\": 41, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 10, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 11, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 12, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 13, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 14, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 26, \"target\": 15, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"ÃŸ-Amyloid (AÃŸ) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of AÃŸ, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3ÃŸ, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3ÃŸ after exposure to oligomeric AÃŸ in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3ÃŸ, even in the absence of AÃŸ, is sufficient to produce a phenocopy of AÃŸ-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3ÃŸ prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3ÃŸ inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3ÃŸ inhibition robustly decreased the oligomeric AÃŸ load in the mouse brain. All these findings support the idea that GSK3ÃŸ is aberrantly activated by the presence of AÃŸ, and contributes, at least in part, to the neuronal anatomical derangement associated with AÃŸ plaques in AD brains and to AÃŸ pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.\", \"reference\": \"21945540\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GSK3 subgraph\"}, \"source\": 28, \"target\": 2, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"ÃŸ-Amyloid (AÃŸ) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of AÃŸ, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3ÃŸ, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3ÃŸ after exposure to oligomeric AÃŸ in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3ÃŸ, even in the absence of AÃŸ, is sufficient to produce a phenocopy of AÃŸ-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3ÃŸ prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3ÃŸ inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3ÃŸ inhibition robustly decreased the oligomeric AÃŸ load in the mouse brain. All these findings support the idea that GSK3ÃŸ is aberrantly activated by the presence of AÃŸ, and contributes, at least in part, to the neuronal anatomical derangement associated with AÃŸ plaques in AD brains and to AÃŸ pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.\", \"reference\": \"21945540\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 28, \"target\": 2, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"ÃŸ-Amyloid (AÃŸ) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of AÃŸ, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3ÃŸ, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3ÃŸ after exposure to oligomeric AÃŸ in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3ÃŸ, even in the absence of AÃŸ, is sufficient to produce a phenocopy of AÃŸ-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3ÃŸ prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3ÃŸ inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3ÃŸ inhibition robustly decreased the oligomeric AÃŸ load in the mouse brain. All these findings support the idea that GSK3ÃŸ is aberrantly activated by the presence of AÃŸ, and contributes, at least in part, to the neuronal anatomical derangement associated with AÃŸ plaques in AD brains and to AÃŸ pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.\", \"reference\": \"21945540\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GSK3 subgraph\"}, \"source\": 28, \"target\": 2, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"ÃŸ-Amyloid (AÃŸ) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of AÃŸ, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3ÃŸ, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3ÃŸ after exposure to oligomeric AÃŸ in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3ÃŸ, even in the absence of AÃŸ, is sufficient to produce a phenocopy of AÃŸ-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3ÃŸ prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3ÃŸ inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3ÃŸ inhibition robustly decreased the oligomeric AÃŸ load in the mouse brain. All these findings support the idea that GSK3ÃŸ is aberrantly activated by the presence of AÃŸ, and contributes, at least in part, to the neuronal anatomical derangement associated with AÃŸ plaques in AD brains and to AÃŸ pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.\", \"reference\": \"21945540\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 28, \"target\": 2, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis2006\", \"reference\": \"16914869\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 28, \"target\": 2, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis2006\", \"reference\": \"16914869\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 28, \"target\": 2, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis2006\", \"reference\": \"16914869\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 28, \"target\": 2, \"key\": 6}, {\"relation\": \"increases\", \"evidence\": \"Hsp70/Hsc70, a member of the chaperone protein family, interacts with Tau protein and mediates proper folding of Tau and can promote degradation of Tau protein under certain circumstances. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem2007\", \"reference\": \"17954934\"}, \"object\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 30, \"target\": 26, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Hsp70/Hsc70, a member of the chaperone protein family, interacts with Tau protein and mediates proper folding of Tau and can promote degradation of Tau protein under certain circumstances. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem2007\", \"reference\": \"17954934\"}, \"object\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"Ubiquitin degradation subgraph\"}, \"source\": 30, \"target\": 26, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Hsp70/Hsc70, a member of the chaperone protein family, interacts with Tau protein and mediates proper folding of Tau and can promote degradation of Tau protein under certain circumstances.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem2007\", \"reference\": \"17954934\"}, \"object\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 30, \"target\": 26, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Hsp70/Hsc70, a member of the chaperone protein family, interacts with Tau protein and mediates proper folding of Tau and can promote degradation of Tau protein under certain circumstances.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Biol Chem2007\", \"reference\": \"17954934\"}, \"object\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"Chaperone subgraph\"}, \"source\": 30, \"target\": 26, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Neurochem1997\", \"reference\": \"9202310\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"MAPK-JNK subgraph\"}, \"source\": 33, \"target\": 11, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Neurochem1997\", \"reference\": \"9202310\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 33, \"target\": 11, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Neurochem1997\", \"reference\": \"9202310\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"MAPK-JNK subgraph\"}, \"source\": 33, \"target\": 12, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Neurochem1997\", \"reference\": \"9202310\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 33, \"target\": 12, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Neurochem1997\", \"reference\": \"9202310\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"MAPK-JNK subgraph\"}, \"source\": 33, \"target\": 15, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Neurochem1997\", \"reference\": \"9202310\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 33, \"target\": 15, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3ÃƒÅ¸, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes\", \"citation\": {\"type\": \"PubMed\", \"name\": \"BMB Rep. 2010 Oct;43(10):656-63.\", \"reference\": \"21034527\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"tscript\", \"namespace\": \"bel\"}}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 37, \"target\": 2, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3ÃƒÅ¸, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes\", \"citation\": {\"type\": \"PubMed\", \"name\": \"BMB Rep. 2010 Oct;43(10):656-63.\", \"reference\": \"21034527\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"tscript\", \"namespace\": \"bel\"}}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {}, \"source\": 37, \"target\": 21, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3ÃƒÅ¸, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes\", \"citation\": {\"type\": \"PubMed\", \"name\": \"BMB Rep. 2010 Oct;43(10):656-63.\", \"reference\": \"21034527\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"tscript\", \"namespace\": \"bel\"}}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {}, \"source\": 37, \"target\": 21, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurosci Lett. 2009 May 22;455(3):191-4. doi: 10.1016/j.neulet.2009.03.066. Epub 2009 Mar 25.\", \"reference\": \"19429119\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 39, \"target\": 2, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurosci Lett. 2009 May 22;455(3):191-4. doi: 10.1016/j.neulet.2009.03.066. Epub 2009 Mar 25.\", \"reference\": \"19429119\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 39, \"target\": 2, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurosci Lett. 2009 May 22;455(3):191-4. doi: 10.1016/j.neulet.2009.03.066. Epub 2009 Mar 25.\", \"reference\": \"19429119\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Leptin subgraph\"}, \"source\": 39, \"target\": 2, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Treatment with leptin reversed the 27-OHC-induced increase in Abeta and phosphorylated tau by decreasing the levels of BACE-1 and GSK-3beta respectively.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Alzheimer's disease2010\", \"reference\": \"20157255\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 39, \"target\": 2, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"Treatment with leptin reversed the 27-OHC-induced increase in Abeta and phosphorylated tau by decreasing the levels of BACE-1 and GSK-3beta respectively.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Alzheimer's disease2010\", \"reference\": \"20157255\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 39, \"target\": 26, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Results demonstrate that the beta-carboline compounds (1) potently reduce the expression of all three phosphorylated forms of tau protein, and (2) inhibit the DYRK1A catalyzed direct phosphorylation of tau protein on serine 396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"PLoS One2011\", \"reference\": \"21573099\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"DYRK1A subgraph\"}, \"source\": 42, \"target\": 12, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Results demonstrate that the beta-carboline compounds (1) potently reduce the expression of all three phosphorylated forms of tau protein, and (2) inhibit the DYRK1A catalyzed direct phosphorylation of tau protein on serine 396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"PLoS One2011\", \"reference\": \"21573099\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 42, \"target\": 12, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Diverse types of proteins have been identified as the substrates of Dyrk1A, including transcription factors, including NF-AT and Forkhead , several\\\\ endocytosis and synaptic vesicle recycling proteins, such as dynamin 1 and amphiphysin 1\\\\ , and cytosolic proteins, such as APP and tau\\\\ , implying that Dyrk1A participates in various biological responses.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Exp Neurobiol. 2011 Mar;20(1):35-44. Epub 2011 Mar 31.\", \"reference\": \"22110360\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Condition\": \"Normal Healthy State\", \"Subgraph\": \"DYRK1A subgraph\"}, \"source\": 42, \"target\": 26, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Diverse types of proteins have been identified as the substrates of Dyrk1A, including transcription factors, including NF-AT and Forkhead , several\\\\ endocytosis and synaptic vesicle recycling proteins, such as dynamin 1 and amphiphysin 1\\\\ , and cytosolic proteins, such as APP and tau\\\\ , implying that Dyrk1A participates in various biological responses.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Exp Neurobiol. 2011 Mar;20(1):35-44. Epub 2011 Mar 31.\", \"reference\": \"22110360\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Condition\": \"Normal Healthy State\", \"Subgraph\": \"Tau protein subgraph\"}, \"source\": 42, \"target\": 26, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 10, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 10, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 11, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 11, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neurochemistry2001\", \"reference\": \"11181841\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 11, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neurochemistry2001\", \"reference\": \"11181841\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 11, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 12, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 12, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neurochemistry2001\", \"reference\": \"11181841\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 12, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neurochemistry2001\", \"reference\": \"11181841\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 12, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 13, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 13, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neurochemistry2001\", \"reference\": \"11181841\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 13, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Neurochemistry2001\", \"reference\": \"11181841\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 13, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 14, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 14, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 43, \"target\": 15, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 43, \"target\": 15, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of AÃƒÅ¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with AÃƒÅ¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis. 2010;22(3):741-63\", \"reference\": \"20847424\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 44, \"target\": 2, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of AÃƒÅ¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with AÃƒÅ¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis. 2010;22(3):741-63\", \"reference\": \"20847424\"}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Beta-Catenin subgraph\"}, \"source\": 44, \"target\": 2, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [bisphenol A results in increased expression of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18462866\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 1, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [bisphenol A results in increased expression of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15899841\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 1, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [bisphenol A results in increased expression of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18347134\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 1, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [bisphenol A results in increased expression of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"23222814\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 1, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin results in decreased phosphorylation of GSK3B protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18790744\"}, \"annotations\": {}, \"source\": 45, \"target\": 2, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin results in decreased phosphorylation of GSK3B protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19573523\"}, \"annotations\": {}, \"source\": 45, \"target\": 2, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin results in decreased phosphorylation of GSK3B protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18006147\"}, \"annotations\": {}, \"source\": 45, \"target\": 2, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [Calcitriol results in increased expression of and results in increased activity of CYP3A4 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17270371\"}, \"annotations\": {}, \"source\": 45, \"target\": 6, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [Calcitriol results in increased expression of and results in increased activity of CYP3A4 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20816778\"}, \"annotations\": {}, \"source\": 45, \"target\": 6, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [Calcitriol results in increased expression of and results in increased activity of CYP3A4 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17210444\"}, \"annotations\": {}, \"source\": 45, \"target\": 6, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [Calcitriol results in increased expression of and results in increased activity of CYP3A4 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17965521\"}, \"annotations\": {}, \"source\": 45, \"target\": 6, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [AR protein results in increased expression of KLK3 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18462866\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [AR protein results in increased expression of KLK3 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12497104\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 8, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [AR protein results in increased expression of KLK3 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18676361\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 8, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [AR protein results in increased expression of KLK3 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18719366\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 8, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"Curcumin inhibits the reaction [AR protein results in increased expression of KLK3 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22258452\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 45, \"target\": 8, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone results in decreased expression of ESR1 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22475373\"}, \"annotations\": {}, \"source\": 46, \"target\": 1, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone results in decreased expression of ESR1 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15001543\"}, \"annotations\": {}, \"source\": 46, \"target\": 1, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone results in decreased expression of ESR1 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20686183\"}, \"annotations\": {}, \"source\": 46, \"target\": 1, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [Progesterone results in increased phosphorylation of GSK3B protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16882987\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 46, \"target\": 2, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16837568\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22652334\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12235278\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16049126\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15466163\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17041008\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15860655\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18332045\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"Mifepristone inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10219967\"}, \"annotations\": {}, \"source\": 46, \"target\": 6, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16679488\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11535548\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11867264\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14617632\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14699072\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15521089\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15807179\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15842231\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15941852\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15961563\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16497877\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16604479\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 11}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16798746\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17203231\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 13}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17299137\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 14}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17350824\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 15}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17395694\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 16}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17654759\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 17}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17872375\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 18}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18976723\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 19}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19059307\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 20}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19432593\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 21}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20362049\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 22}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20435135\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 23}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21256200\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 24}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21543282\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 25}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"9751507\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 26}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15161930\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 27}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16790557\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 28}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19350480\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 29}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15653758\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 30}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16680078\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 31}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16790557\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 32}, {\"relation\": \"decreases\", \"evidence\": \"ARID5A protein inhibits the reaction [Raloxifene results in increased activity of ESR1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17348974\"}, \"annotations\": {}, \"source\": 47, \"target\": 1, \"key\": 33}, {\"relation\": \"decreases\", \"evidence\": \"Raloxifene results in decreased activity of CYP3A4 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16959878\"}, \"annotations\": {}, \"source\": 47, \"target\": 6, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Raloxifene results in decreased activity of CYP3A4 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"22429462\"}, \"annotations\": {}, \"source\": 47, \"target\": 6, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Raloxifene results in decreased activity of CYP3A4 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15860655\"}, \"annotations\": {}, \"source\": 47, \"target\": 6, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Raloxifene results in decreased activity of CYP3A4 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17497897\"}, \"annotations\": {}, \"source\": 47, \"target\": 6, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"Raloxifene results in decreased expression of AR mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11867264\"}, \"annotations\": {}, \"source\": 47, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Raloxifene results in decreased expression of AR mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15731164\"}, \"annotations\": {}, \"source\": 47, \"target\": 8, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Raloxifene results in decreased expression of AR mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16837883\"}, \"annotations\": {}, \"source\": 47, \"target\": 8, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"These data suggest that aberrant glycosylation of tau in AD might be involved in neurofibrillary degeneration by promoting abnormal hyperphosphorylation by cdk5 and GSK-3beta.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 48, \"target\": 2, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"These data suggest that aberrant glycosylation of tau in AD might be involved in neurofibrillary degeneration by promoting abnormal hyperphosphorylation by cdk5 and GSK-3beta.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 48, \"target\": 2, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 48, \"target\": 11, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 48, \"target\": 11, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 48, \"target\": 13, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 48, \"target\": 13, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 48, \"target\": 13, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 48, \"target\": 13, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 48, \"target\": 14, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 48, \"target\": 14, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 48, \"target\": 15, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS Lett2002\", \"reference\": \"12387894\"}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 48, \"target\": 15, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"celecoxib results in decreased phosphorylation of GSK3B protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17257745\"}, \"annotations\": {\"Species\": \"9606\"}, \"source\": 49, \"target\": 2, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"celecoxib results in decreased expression of AR protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15570007\"}, \"annotations\": {}, \"source\": 49, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"celecoxib results in decreased expression of AR protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17908994\"}, \"annotations\": {}, \"source\": 49, \"target\": 8, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"[celecoxib results in decreased activity of and results in decreased expression of PTGS2 protein] which results in increased expression of PPARG\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19522023\"}, \"annotations\": {}, \"source\": 49, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"[celecoxib results in decreased activity of and results in decreased expression of PTGS2 protein] which results in increased expression of PPARG\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16052515\"}, \"annotations\": {}, \"source\": 49, \"target\": 20, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"[celecoxib results in decreased activity of and results in decreased expression of PTGS2 protein] which results in increased expression of PPARG\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12960143\"}, \"annotations\": {}, \"source\": 49, \"target\": 20, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"[celecoxib results in decreased activity of and results in decreased expression of PTGS2 protein] which results in increased expression of PPARG\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19247274\"}, \"annotations\": {}, \"source\": 49, \"target\": 20, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"[celecoxib results in decreased activity of and results in decreased expression of PTGS2 protein] which results in increased expression of PPARG\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19522023\"}, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 49, \"target\": 20, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"rosiglitazone results in decreased activity of GSK3B protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19201691\"}, \"annotations\": {}, \"source\": 50, \"target\": 2, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"rosiglitazone results in decreased activity of GSK3B protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19621015\"}, \"annotations\": {}, \"source\": 50, \"target\": 2, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"rosiglitazone results in decreased activity of GSK3B protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19566839\"}, \"annotations\": {}, \"source\": 50, \"target\": 2, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"rosiglitazone results in decreased activity of CYP3A4 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12642470\"}, \"annotations\": {}, \"source\": 50, \"target\": 6, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"rosiglitazone results in decreased activity of CYP3A4 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16837568\"}, \"annotations\": {}, \"source\": 50, \"target\": 6, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"rosiglitazone results in decreased activity of CYP3A4 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15860655\"}, \"annotations\": {}, \"source\": 50, \"target\": 6, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10393202\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10529360\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10636887\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10799317\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10813377\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10871190\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"10882139\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11416043\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11714655\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 8}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"11752099\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 9}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12083418\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 10}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12401879\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 11}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12414803\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 12}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12897060\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 13}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"12970094\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 14}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14709329\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 15}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"14744930\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 16}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15073165\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 17}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15334371\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 18}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15381068\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 19}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15504970\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 20}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15640776\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 21}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15684043\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 22}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15715931\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 23}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"15751073\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 24}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16034372\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 25}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16215386\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 26}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16321982\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 27}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16425225\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 28}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16499875\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 29}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16539667\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 30}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16609881\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 31}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16617452\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 32}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16750656\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 33}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16757903\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 34}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16775433\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 35}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16799780\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 36}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"16982809\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 37}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17107731\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 38}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17188145\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 39}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17245590\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 40}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17261469\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 41}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17264099\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 42}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17266988\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 43}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17437057\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 44}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17445544\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 45}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17453334\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 46}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17456854\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 47}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17461532\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 48}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17475839\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 49}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17506947\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 50}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17555498\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 51}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17594812\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 52}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17597835\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 53}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17614770\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 54}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17932317\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 55}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17950491\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 56}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17951467\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 57}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"17970706\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 58}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18053798\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 59}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18155663\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 60}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18238811\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 61}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18269641\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 62}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18269830\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 63}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18276752\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 64}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18387855\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 65}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18562925\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 66}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18565938\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 67}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18599600\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 68}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18652780\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 69}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18700276\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 70}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18948087\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 71}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18954260\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 72}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"18998217\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 73}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19147827\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 74}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19193937\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 75}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19201733\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 76}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19226370\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 77}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19277604\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 78}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19321784\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 79}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19356226\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 80}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19451898\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 81}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19464576\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 82}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19474210\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 83}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19508902\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 84}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19520784\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 85}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19631733\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 86}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19632256\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 87}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19641680\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 88}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19666838\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 89}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19706614\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 90}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19850645\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 91}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19902320\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 92}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19906946\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 93}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"19951259\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 94}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20003221\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 95}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20007851\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 96}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20032081\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 97}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20068562\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 98}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20336061\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 99}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20506517\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 100}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20507283\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 101}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20733306\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 102}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20814411\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 103}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20840543\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 104}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20860658\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 105}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"20965162\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 106}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21034554\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 107}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21113404\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 108}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21172411\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 109}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21212935\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 110}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21269478\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 111}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"21347706\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 112}, {\"relation\": \"decreases\", \"evidence\": \"Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PPARG protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reference from AD_HBP Data\", \"reference\": \"2135281\"}, \"annotations\": {}, \"source\": 50, \"target\": 20, \"key\": 113}, {\"relation\": \"increases\", \"evidence\": \"We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 Î¼g/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3β (GSK-3β) activation, as determined by phosphatase activity assay and GSK-3β phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis. 2011;24(3):525-35\", \"reference\": \"21297267\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 51, \"target\": 10, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 Î¼g/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3β (GSK-3β) activation, as determined by phosphatase activity assay and GSK-3β phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis. 2011;24(3):525-35\", \"reference\": \"21297267\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 51, \"target\": 11, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 Î¼g/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3β (GSK-3β) activation, as determined by phosphatase activity assay and GSK-3β phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis. 2011;24(3):525-35\", \"reference\": \"21297267\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 51, \"target\": 12, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 Î¼g/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3β (GSK-3β) activation, as determined by phosphatase activity assay and GSK-3β phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis. 2011;24(3):525-35\", \"reference\": \"21297267\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 51, \"target\": 13, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 Î¼g/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3β (GSK-3β) activation, as determined by phosphatase activity assay and GSK-3β phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis. 2011;24(3):525-35\", \"reference\": \"21297267\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 51, \"target\": 14, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 Î¼g/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3β (GSK-3β) activation, as determined by phosphatase activity assay and GSK-3β phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"J Alzheimers Dis. 2011;24(3):525-35\", \"reference\": \"21297267\"}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 51, \"target\": 15, \"key\": 0}]};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "In this case, we were able to infer connections that not only gave the Estrogen subgraph more context, but also connected the individual components"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Conclusions\n",
    "\n",
    "A final touch to the subgraph might be to infer connections between nodes that have just been added. This can be done with [pbt.mutation.expand_internal](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.expand_internal) which allows for specification of edge filters, or with [pbt.mutation.expand_internal_causal](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.expand_internal_causal) that is a thin wrapper, giving the edge filter [pbt.filters.keep_causal_edges](http://pybel-tools.readthedocs.io/en/latest/filters.html#pybel_tools.filters.edge_filters.keep_causal_edges). Again, expansion on unqualified edges and opening with the central dogma can make this expanded subgraph easier to interpret."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
